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Abstract 
Membrane proteins comprise of 50% of all pharmaceutical targets in the human 
genome.  These proteins reside in equilibrium between resting and active states that are 
responsible for various intracellular signaling. We are interested in studying a type of 
membrane protein belonging to the G-protein coupled receptor (GPCR) family named 
calcitonin receptor-like receptor (CLR). When associated with a single pass membrane 
protein called receptor activity modifying protein 1 (RAMP1), the CLR-RAMP1 
complex forms a specific receptor for calcitonin gene-related peptide (CGRP). 
Dysregulation of this receptor complex is linked to various disease states including 
migraine and acute coronary syndrome (ACS). Small molecule antagonists targeting 
CLR-RAMP1 complex have been shown to be effective in treating acute migraines, 
however, they are only limited to intravenous delivery. Therefore, it is very important to 
obtain a detail understanding on how these receptors interact to form the functional 
receptor for superior drug design.  
 Membrane proteins are extremely difficult to study due to their water insoluble 
nature. To overcome this limitation, we developed several tools to assist our research. 
One important mechanism that regulates membrane protein activation is receptor 
oligomerization. In order to gain an understanding and identify residues that govern 
receptor oligomerization in a straightforward and high throughput fashion, we 
developed E. coli transcription factor AraC-based methods named AraTM and DN-
AraTM which look at receptor homo- and heterodimerization respectively. By using 
AraTM assay, we were able to identify a specific juxtamembrane region within the 
cytosolic domain (A375-P394) of receptor for advanced glycation endproducts (RAGE) 
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which mediates its homodimerization. Moreover, we also developed a T7-based 
expression vector (pOmpF) using an engineered fragment of outer membrane protein F 
(OmpF) as the fusion protein to direct full-length membrane protein overexpression in 
E. coli for high-resolution structure determination. Utilizing pOmpF vector, we 
successfully purified thermally stable RAMP1 protein in detergent Fos-choline 15 
(FC15). By using circular dichroism, dynamic light scattering, and tryptophan 
fluorescence spectroscopy, we were able to show that the purified RAMP1 protein has a 
native tertiary structure consisting of disulfide bonds with 90% helical content.  
 Finally, using sequence-directed searches of transmembrane structural 
databases, we identified a P-x-x-x-T motif interface that is conserved in RAMP1 among 
different species as well as between different human RAMPs. By applying cAMP 
signaling assay, in vivo bioluminescent resonance energy transfer assay, and zebrafish 
RAMP1 phenotypic knockdown and rescue experiments, we were able to show that this 
predicted P-x-x-x-T motif plays a critical role in CLR-RAMP1 association and function. 
Altogether, this work not only provides innovative tools to improve membrane protein 
research but also sheds light on understanding the structural basis for CLR-RAMP1 
receptor signaling.  
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Chapter 1 
INTRODUCTION 
 
The cells of virtually every living organism are surrounded by a phospholipid 
bilayer membrane, acting as a continuous hydrophobic barrier which retains various 
proteins, ions, and other biomolecules inside the cell and prevents unwanted foreign 
substances from entering the cell. However cells must be able to communicate and 
receive instructions from neighboring cells and the surrounding environment in order to 
function properly. Communication is achieved by membrane receptor proteins which 
span the cell membrane, recognize signals from the outside, and trigger intracellular 
changes through signal transduction. This process plays critical roles in various aspects 
of cellular activity such as wound healing, cell development, and generating an immune 
response. Membrane proteins comprise 30% of all proteins in the human genome and 
50% of all pharmaceutical targets, however less than 0.3% of protein structures in the 
Protein Data Bank (PDB; www.rcsb.org) are membrane proteins (1). This is largely due 
to the inability to obtain sufficient quantities of membrane protein sample because of 
their insolubility in aqueous solutions and low abundance in their native membrane 
environment, therefore complicating efforts aimed at developing new pharmaceuticals 
(1-4).  
In terms of pharmacology, G-protein coupled receptors (GPCRs) are an 
incredibly important type of membrane protein because they composed over 40% of 
clinically approved drug targets currently (5). GPCRs are a superfamily of seven 
transmembrane spanning proteins that are associated with a variety of intracellular 
signaling including hormones, neurotransmitters, light, odor, and taste via interaction 
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with guanine nucleotide binding proteins (G-proteins) (6). As shown in Figure 1.1, 
binding of GPCR ligands results in conformational changes in GPCRs that facilitate the 
exchange of guanosine diphosphate (GDP) to guanosine triphosphate (GTP) on the 
heterotrimeric G protein Gα subunit which leads to the dissociation of Gα from the Gβ 
and Gγ subunit for subsequence signaling (7, 8). Based on Gene Ontology and Celera’s 
Panther Classification, GPCR can be categorized into three main classes: Rhodopsin-
like (class A), Secretin-like (class B), and Glutamate-like (class C), where Rhodopsin-
like class accounts for about 85% of the known GPCRs genomes (9). Although a 
number of active and inactive crystal structures of class A GPCR are available, they 
were limited usage for studying class B GPCR due to the lack of sequence conservation 
between these two classes (10). Up to date, there is no solved full-length class B GPCR 
crystal structure; therefore, there remains a lot of interest and opportunities in 
understanding how class B GPCRs function and signal.  
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Figure 1. 1. The G protein cycle. Ligand binding to the G protein-coupled receptor 
(GPCR) leads to exchange of GDP on the Gα subunit and dissociation of the Gα and 
Gβγ heterodimer. Both Gα-GTP and Gβγ may regulate downstream effectors. GTP 
hydrolysis by the Gα subunit results in reassociation of GDP-bound Gα with Gβγ 
heterodimer and the GPCR, thus completing the cycle. RGS (regulator of G protein 
signaling) proteins accelerate the rate of GTP bydrolysis by the Gα subunit (7). 
 
Calcitonin receptor-like receptor (CLR) is a class B GPCR with a 22 amino acid 
N-terminus signal peptide, a 124 amino acid extracellular domain with three N-linked 
glycosylation sites and three pairs of disulfide bonds, seven α-helical transmembrane 
domains, and a 73 amino acid cytosolic tail (11-13). CLR is linked with diverse disease 
conditions such as osteoporosis, diabetes, obesity, venous insufficiency, and 
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cardiovascular disorder (14). As shown in Figure 1.2, CLR alone does not recognize 
any ligand, thus the ligand-specificity of this receptor is dependent on its interaction 
with a group of accessory membrane proteins named receptor activity modifying 
proteins (RAMPs) (15-18). There are three types of RAMPs (RAMP1, RAMP2 and 
RAMP3), which share less than 30% sequence identity (18). The RAMPs are 148-175 
amino acids in size with a cleavable N-terminal signaling peptide and similar topology: 
a large N-terminal extracellular domain (~100aa), a single transmembrane spanning 
domain (~20aa) and a short C-terminal intracellular domain (~10aa) (19). Associating 
with RAMP1 or RAMP2/3, CLR forms a calcitonin gene-related peptide (CGRP) 
receptor or an adrenomedullin (AM) receptor respectively (18). CGRP is one of the 
most potent vasodilators discovered thus far (20). Increased cranial circulation of CGRP 
has been associated with migraines therefore antagonism of CGRP receptors has 
become an important target for migraine treatment (21). Nevertheless, current 
antimigraine treatments such as sumatriptan cause vasoconstriction and other CLR 
antagonist chemical-based drugs developed by several pharmaceutical companies either 
exhibit poor oral bioavailability (olcegepant) or cause liver damage (telcagepant) (21, 
22). One major challenge to design small molecule antagonist against class B GPCRs is 
the endogenous peptide-based ligand nature of these receptors, which involves 
competing a larger molecule which has more point of interaction with the receptor with 
a smaller molecule (23). Therefore, in order to design more effective migraine 
medications which possess high receptor selectivity, it is critical to understand how 
CLR and RAMP1 interact to form the ligand-binding pocket and how this receptor 
mediates signal transduction.  
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Figure 1. 2. The CGRP/adrenomedullin (AM) receptor model. The calcitonin receptor-
like receptor (CLR) component is common to all three receptors and is a G protein-
coupled 7-transmembrane receptor. The three RAMP components are single 
transmembrane domain proteins. The active receptor is a functional heterodimer of one 
CLR complexed with a RAMP, at the cell membrane. The interaction of RAMP1 with 
CL produces a CGRP receptor, RAMP2 with CLR an AM receptor, and RAMP3 with 
CLR a CGRP/AM receptor. The proposed receptor component protein (RCP), which is 
suggested to allow coupling to intracellular signaling pathways, is also included (15). 
 
Efforts have been made to investigate the role different RAMP1 domains play in 
the formation of a functional CGRP receptor. In summary, RAMP1 extracellular 
domain alone can N-glycosylate CLR, is able to form a functional receptor unit with 
CLR and traffic the receptor to plasma membrane; however, the half maximum 
effective concentration is increased about 4000 fold compared to full length RAMP1 
(24). This indicates that the remaining domains of RAMP1 play a significant role in 
CGRP binding and signaling. Steiner et al. showed that by deleting the short 
intracellular tail of RAMP1 had no effect in signaling (25). Moreover, in 2010, a high-
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resolution structure of RAMP1-CLR extracellular domain in complex with bound 
chemical based antagonist was solved by ter Haar et al. (12). They demonstrated this 
complex was able to compete with the wild-type receptor binding to CGRP using 
radioligand displacement binding assay, but with a much lower binding affinity (12). 
This means that this structure does not fully recapitulated the binding of CGRP to CLR-
RAMP1 complex. They also crystallized the soluble portion of the receptor in complex 
with antagonist olcegepant or telcagepant, but the size of the antagonist is much smaller 
than the size of the CGRP, so it does not provide a full picture for CGRP-receptor 
binding. All of the above results point toward the specific interaction of CLR-RAMP1 
being governed by their TM domains. Therefore, in order to understand how CLR and 
RAMP1 assemble to form a functional receptor for CGRP, we need to study them from 
a perspective that is in context with their TM domains. 
One means of understanding how external signals are transduced by membrane 
receptors is through the analysis of receptor homo- and heterodimerization. Receptor 
homo- and heterodimerization is a key mechanism that regulates transmembrane signal 
transduction through a coordinated process that involves ligand binding in the 
extracellular (EX) domain as well as conformational changes in the receptor 
transmembrane (TM) and cytoplasmic (CYTO) domains (26). For GPCRs, it had been 
proposed and proven in class A GPCRs that GPCR dimerization can play a role in 
receptor maturation, become a target for ligand induced dynamic regulation, lead to 
both positive and negative ligand binding cooperativity, change G-protein selectivity, 
and promote co-internalization of two receptors (27). Several classes of type I 
transmembrane receptors, including neuropilins and integrins, exist in a regulated 
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equilibrium between homo- and heterodimeric states which defines the inactive or 
activated forms of the co-receptor complex (28, 29). Within the TM domain of integrin 
αIIb or β3, mutations that promote preferential TM homodimer formation or destabilize 
the heterodimeric interface can result in receptor activation (28). Thus, in order to 
understand the basis for transmembrane signal transduction, it is essential to 
characterize the interplay between specific homo- and heterodimeric interactions 
involving TM and juxtamembrane (CYTO, EX) domains. 
 Numerous biological tools have been developed to study membrane receptor 
interactions and understand the basis for transmembrane signaling, including 
polyacrylamide gel-shift assay, analytical ultracentrifugation, and Forster resonance 
energy transfer (FRET). Among these methods, transcription factor-based selection 
systems have the advantage of straightforward implementation, their ability to be 
performed in vivo, high sensitivity, and rapid access to identify importance interfaces 
and domains within membrane receptors in defining homo- and heterodimeric states 
(30, 31). However, popular transcription factor-based methods such as TOXCAT and 
GALLEX rely on transcription factors (ToxR for TOXCAT, LexA for GALLEX) with 
type II orientation, in which the N-terminal DNA-binding domain is expressed as a 
fusion to a C-terminal TM domain of interest (30, 31). Thus, the C-terminal TM domain 
acts as a signal peptide to direct membrane trafficking and integration, and any 
modification of the TM domain, including addition of CYTO and EX domains, can 
prevent proper membrane integration. As a result, bacterial assays TOXCAT and 
GALLEX are limited to analysis of only isolated TM domains and these TM domain 
interactions were studied in a reverse orientation relative to their native states.  
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Another aspect of understanding how membrane receptors signal is through 
high-resolution protein structure determination by X-ray crystallography. X-ray 
crystallography is a technique in which beams of X-ray are bombarded at a protein 
crystal and the scattering pattern of the X-ray are collected and analyzed to generate a 
3D protein structure (32). The most difficult part of X-ray crystallography is the 
formation of protein crystal. Due to their irregularly shaped surfaces and heterogeneity, 
it requires high purity (>97%) and large amounts of protein sample to empirically 
determine the ideal crystallization condition for different proteins (33, 34). However, 
obtaining high yields of homogeneous, soluble membrane protein is a major challenge 
due to their low abundance in their native membrane environment (3, 4, 35). Numerous 
approaches have been developed to improve the yield and recovery of integral 
membrane proteins. Among all the strategies to obtain high yield membrane proteins, E. 
coli-based strategies utilizing protein fusions are the most popular method for large-
scale, recombinant membrane protein expression (36, 37). E. coli has several 
advantages for membrane protein overexpression: defined growth media is relatively 
inexpensive, numerous genetic tools are available for straightforward cell and target 
protein manipulation, and several expression conditions are established for large-scale 
synthesis (38, 39). However, in all cases, no single fusion protein was identified that 
gave consistently high expression independent of the particular target membrane 
protein. Furthermore, the effectiveness of many fusion protein vectors is only limited to 
expression of fragments of, rather than full-length membrane proteins.  
To address these limitations of investigating how membrane receptors signal, we 
developed new approaches based on the E. coli AraC transcription factor to investigate 
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EX-TM-CYTO receptor domain homodimerization (Chapter 2) and heterodimeriztion 
(Chapter 3). We also developed a T7-based expression vector (pOmpF) using an 
engineered fragment of outer membrane protein F (OmpF) as the fusion protein to 
direct full-length membrane protein overexpression in E. coli for high-resolution 
structure determination (Chapter 4). Utilizing these novel tools and existing membrane 
receptor studying tools such as bioluminescence resonance energy transfer (BRET) and 
circular dichroism, we identified a specific sequence motif in RAMP1 TM domain that 
plays a significant role in CLR-RAMP1 association and signaling (Chapter 5). Finally, 
potential research directions are proposed in Chapter 6.  
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Chapter 2  
IDENTIFYING KEY JUXTAMEMBRANE INTERACTIONS IN  
CELL MEMBRANES USING ARAC-BASED TRANSCRIPTIONAL  
REPORTER ASSAY (ARATM) 
 
The work described in this chapter has been published in “Identify Key   
Juxtamembrane Interactions in Cell Membrane Using AraC-based Transcriptional  
Reporter Assay (AraTM)” by Pin-Chuan Su and Bryan W. Berger, The Journal of  
Biological Chemistry 2012 287 (37), 31515-31526.  
 
 
 
Dimerization is a key regulatory mechanism in activation of transmembrane 
(TM) receptors during signal transduction. This process involves a coordinated 
interplay between extracellular (EX), TM, and cytoplasmic (CYTO) regions to form a 
specific interface required for both ligand binding and intracellular signaling to occur. 
While several transcriptional activator-based methods exist for investigating TM 
interactions in bacterial membranes, expression of TM chimera in these methods occurs 
in a reverse orientation, and are limited to only TM domains for proper membrane 
trafficking and integration. We therefore developed a new, AraC-based transcriptional 
reporter assay (AraTM) that expresses EX-TM-CYTO chimera in their native 
orientation, thereby enabling membrane trafficking to occur independent of the TM 
chimera used as well as permitting analysis of EX-TM-CYTO interactions in biological 
membranes. Using integrin αIIb TM-CYTO as a model, we observe a large increase in 
homodimerization for the constitutively active TM mutant L980A relative to wild-type in 
the TM-CYTO construct (A963-E1008). We also characterized the receptor for 
advanced glycation endproducts (RAGE), whose homooligomeric state is critical in 
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ligand recognition, and find the specific juxtamembrane region within the CYTO (A375-
P394) mediates homodimerization, and is dominant over effects observed when the 
extracellular C2 domain is included. Furthermore, we find good agreement between 
our AraTM measurements in bacterial membranes and BRET measurements made on 
corresponding RAGE constructs expressed in transfected HEK293 cells. Overall, the 
AraTM assay provides a new approach to identify specific interactions between 
receptor EX-TM-CYTO domains in biological membranes that are important in 
regulation of signal transduction. 
 
 
2.1 Introduction 
 
Transmembrane receptors play critical roles in regulating diverse biological 
processes, including cell-cell communication, adhesion, and proliferation. In particular, 
receptor dimerization is a key mechanism by which extracellular cues such as ligand 
binding are communicated across the cell membrane to activate intracellular signaling 
processes through formation of a multimeric, signaling complex (1). Recent work has 
illustrated the importance of specific interfaces involving transmembrane (TM) regions 
of single- and multi-pass membrane proteins in stabilizing receptor signaling 
complexes, as well as cooperative interactions between TM, cytoplasmic (CYTO) and 
extracellular (EX) regions that regulate ligand-dependent signal transduction across cell 
membranes (2). One such example are the integrins, which are a family of 
heterodimeric, cell surface receptors involved in cell adhesion and cell-cell 
communication (3). For platelet integrin αIIbβ3, heterodimeric complexes stabilized 
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through specific EX, TM and CYTO interactions occur in the inactive form, and both 
αIIb and β3 undergo homooligomeric clustering into larger focal adhesion complexes 
upon inside-out activation (3–7). Likewise, basic residues in the juxtamembrane (JM) 
region of glycoprotein Ib CYTO are important in stabilizing the glycoprotein Ib-IX 
complex (8, 9). In the case of platelet-derived growth factor β receptor (PDGFβ), while 
TM domain interactions involving a conserved, GX3G interface drive 
homodimerization, purified peptide corresponding to a JM-TM-CYTO fragment of 
PDGFβ forms a obligate dimer, which suggests the CYTO rather than the TM enforces 
the stoichiometry of the signaling complex (10). Thus, the interplay between TM, 
CYTO and EX interactions is central to defining both the active and inactive forms of 
oligomeric receptor complexes during signal transduction. 
Transcription factor-based selection systems such as TOXCAT, POSSYCAT, 
TOXluc and GALLEX are essential tools dimerization (11–15). In particular, TOXCAT 
and POSSYCAT are based on TM domain fusions to ToxR, which is a transmembrane 
transcription factor from V. cholera  (16). Upon dimerization, ToxR binds the ctx 
promoter and activates gene transcription through its N-terminal DNA binding domain 
(16). Unlike most single-pass TM receptors, which contain an N-terminal signal peptide 
to direct membrane insertion (type I) as well as a TM domain (17), ToxR is a type II 
integral membrane protein, where the C-terminal TM domain functions to direct 
insertion and integration into the cytoplasmic membrane (18). For TOXCAT, TOXluc, 
and POSSYCAT, the TM domain of ToxR is replaced with a given TM domain of 
interest and the periplasmic domain is replaced with a truncated form of maltose-
binding protein (MBP) that lacks its N-terminal signal peptide sequence (12–14). For 
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each assay, the heterologous TM domain of interest functions as a surrogate signal 
peptide to direct insertion of the TM-MBP fusion in an inverted orientation in the inner 
membrane of E. coli  (12–14). The orientation of expressed chimera using ToxR is 
illustrated in Fig. 1. The extent of TM-mediated oligomerization is reflected in the level 
of chloramphenicol acetyltransferase (CAT), β-galactosidase, or luciferase reporter 
gene transcription, all of which are under control of the ctx promoter (12–14). Although 
ToxR-based methods are useful for studying the homodimeric interaction of TM 
domains, the N-terminal DNA-binding domain and type II orientation of ToxR requires 
TM constructs to be expressed as C-terminal fusions directly adjacent to ToxR. Thus, 
addition of EX or CYTO fragments (i.e. EX-TM-CYTO) to ToxR-TM-MBP chimera 
interfere with the ability of the TM to act as a signal peptide to properly traffic chimera 
to the bacterial inner membrane. Additionally, the LexA-based GALLEX method has 
been used with success to investigate TM domain homo- and heterodimerization (11). 
However, as with ToxR, the N-terminal orientation of the LexA DNA binding domain 
necessitates expression of TM-MBP fusions in a reverse orientation in order to insert 
into the bacterial inner membrane (Fig. 1), thereby permitting only TM domains for 
analysis (11). Furthermore, wild-type LexA is a soluble, cytosolic protein, so the 
heterologous TM domain of interest fused to LexA acts as a surrogate signal peptide 
sequence to the MBP fragment to promote insertion of LexA-TM-MBP chimera into the 
bacterial inner membrane in an inverted orientation. Therefore, two limitations of 
current LexA- and ToxR-based methods are that they can only be applied to TM 
domains, and they place TM domains in an inverted orientation in the bacterial inner 
membrane. 
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To address these limitations, we developed a new approach based on the 
Escherichia coli AraC transcription factor to investigate EX-TM-CYTO receptor 
domain homodimerization (AraTM). Unlike ToxR or LexA, AraC contains a C-terminal 
DNA binding domain, and is therefore compatible with expressing EX-TM-CYTO 
fusions in their native orientation as an N-terminal fusion to full-length MBP that 
includes its native signal peptide (Fig. 2.1). The native signal peptide present in MBP 
promotes membrane trafficking, eliminating the need for the TM domain to act as a 
surrogate signal peptide (19). To quantifying dimerization, we developed an eGFP 
reporter under control of the AraC-regulated araBAD promoter that enables 
measurements on whole cells directly from culture. We used integrin αIIb TM-CYTO as 
a model system to benchmark the sensitivity of our assay to specific TM domain 
mutations known to affect homodimerization, and extended this approach to identify 
domains involved in the homodimerization of the receptor for advanced glycation 
endproducts (RAGE). Our results demonstrate the sensitivity of the AraTM method to 
specific point mutations or domain deletions within EX-TM-CYTO constructs, and 
illustrates the utility of AraTM as a complementary approach to other mammalian cell-
based assays to investigate the key domains and motifs responsible for mediating 
receptor dimerization. 
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Figure 2. 1. Organization of AraC and ToxR Fusions Used in TM Interaction Assays. 
In ToxR-based assays (12–14), constructs are configured with ToxR as an N-terminal 
fusion to a TM domain of interest, with mature MBP lacking its signal peptide (SP) 
fused at the C-terminus. ToxR is a type II integral membrane protein (18), and therefore 
the TM domain of interest acts both as a signal peptide to direct membrane trafficking 
as well as membrane integration with the TM domain in a reverse orientation. In the 
AraTM assay, the C-terminal orientation of the DNA-binding domain within AraC 
enables constructs to be expressed with a N-terminal MBP fusion, which includes its 
native signal peptide to direct membrane integration. Thus, AraTM constructs are 
expressed in their native orientation, and membrane integration is decoupled from the 
specific sequence fused to MBP and AraC. 
 
 
 
2.2 Materials and Methods 
 
2.2.1 Subcloning 
 
Unless otherwise stated, standard molecular biology techniques were used. All 
constructs used were verified by DNA sequencing (Department of Genetics Core 
Facility, University of Pennsylvania School of Medicine).  
Plasmid pTrcRSF was generated by amplifying the tac promoter region and 
multiple cloning site from plasmid pTrc99a as a SpeI fragment and RSF origin of 
replication and kanamycin resistance marker from plasmid pRSF1b as a SpeI fragment, 
and ligating these two fragments after SpeI digestion and dephosphorylation of the RSF 
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fragment using CIP. AraC was amplified from plasmid pDS439 and subcloned into 
pTrcRSF as a KpnI/HindIII fragment (20). Full-length MBP, including the N-terminal 
signal peptide sequence for direct trafficking to the periplasmic membrane, was 
amplified from pMAL-p2e (NEB) with the reverse primer containing an HA epitope 
sequence (YPYDVPDYA) and subcloned into pTrcRSF as a NcoI/SacI fragment. A 
fragment of the MCS from pET28a with additional, unique restriction enzyme sites was 
subcloned between SacI and KpnI sites. The resultant plasmid (pAraTM) was used for 
all subsequent experiments, with RAGE and integrin αIIb domains cloned in-frame as 
fusions with MBP and AraC (amino acids 168–293) as SacI/KpnI fragments. Integrin 
αIIb inserts were generated using overlap-extension PCR with synthetic oligonucleotides 
corresponding to the TM and JM regions) and RAGE inserts were amplified from 
plasmid (OriGene) containing the full-length receptor. 
The negative control plasmid pAraCY used for the maltose complementation 
test, which lacks both a TM domain and N-terminal signal peptide sequence, was 
generated by amplifying the MBP fragment lacking N-terminal signal peptide from 
plasmid pToxR1, and ligating after NcoI/SacI digestion into plasmid pTrcRSF 
containing AraC as described above. The negative control plasmid used for all other 
experiments was pTrcRSF. 
The reporter plasmid pAraGFP (Sequence 2.S3) was derived from plasmid 
pDS439 by amplifying a fragment containing the araBAD promoter, MCS, ampicillin 
resistance marker and pBR322 origin of replication. This fragment also contains GFP 
under control of the araBAD promoter, and removes the AraC transcriptional activator 
present on plasmid pDS439. The reporter plasmid pAraGFP was generated by digestion 
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with SpeI and self-ligation with T4 DNA ligase. 
For BRET, full-length human RAGE receptor and RAGE receptor fragments 
were amplified from plasmid (OriGene) and cloned as fragments into plasmidspGFP2 -
N3 as NheI/SacI fragments and pRluc-N2 as BglII/KpnI fragments (BioSignal 
Packard). 
 
 
2.2.2 AraTM dimerization assay 
 
Plasmids pAraTM and pAra-GFP were co-transformed into the AraC-deficient 
E. coli strain SB1676 (The E. coli Genetic Stock Center at Yale University) and 
streaked on selective LB plates (100 µg/ml ampicillin, 50 µg/ml kanamycin). 8 colonies 
were picked for each construct and grown in selective LB media for 16 h at 37 °C. After 
16 h, 1 µl of saturated culture was added to 1 ml of fresh, selective LB media and 
grown for an additional 16 h. 400 µl of cultures from each sample was transferred to a 
black 96-well, clear bottom plate (Greiner) and a series of 2-fold serial dilutions was 
prepared using selective LB media. A600 measurements and GFP fluorescence emissions 
spectra (excitation maximum at 485 nm and emissions maximum at 530 nm) were 
collected using a M200 Infinity plate reader (Tecan). Results are reported as the ratio of 
fluorescence emission at 530 nm to absorbance at 560 nm. 
For FACS measurements, 1 ml of each AraTM construct was grown in selective 
LB (100 µg/ml ampicillin, 50 µg/ml kanamycin) for 16 h at 37 °C and 200 rpm 
overnight. After 16 h, 1 µl of saturated culture was added to 1 ml of selective LB media 
and grown for an additional 16 h. Afterward, cultures were analyzed by flow cytometry 
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(BC FACSCanto II) using 515–545 nm emissions filter for GFP. 100,000 events were 
collected for each construct and the gate was set so that 0% of the negative control 
cells were GFP-positive. 
 
2.2.3 Maltose complementation test 
 
Plasmid pAraTM containingTMinserts were transformed into the MBP-deficient 
E. coli strain MM39, streaked onto selective LB plates (50 µg/ml kanamycin) and 
incubated at 37 °C. The following day, colonies from each plate were grown in selective 
LB media (50 µg/ml kanamycin) at 37 °C and 200 rpm overnight. 5 µl of saturated 
culture from each construct was streaked on selective M9 minimal media plates (50 
µg/ml kanamycin) containing 0.4% (w/v) maltose and incubated at 37 °C for 2 days to 
assess growth (12). 
 
 
2.2.4 Spheroplast protection assay and immunoblotting 
  
For spheroplast immunoblotting, pAraTM plasmids were transformed into 
MBP-deficient MM39 cells and cultures grown to A600 of 0.6 at 37 °C and 200 rpm 
before collecting cells. For immunoblotting to detect AraC-chimera expression from 
whole-cell extracts, plasmid pAraTM containing TM inserts and pAraGFP were 
transformed into SB1676 cells and cultures were grown for 16 h at 37 °C and 200 rpm. 
The following morning, cell cultures were diluted back down to A600 of 0.6 before 
processing cell lysates.  
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20 µl of culture was mixed with 5 µl of 5X Lammeli sample buffer, heated 
briefly at 90 °C, then loaded onto a 12% acrylamide gel. Samples were run for 1 h at 
200 V using Lammeli running buffer, then transferred to a nitrocellulose membrane 
(Amersham Biosciences Hybond ECL) for 90 min, blocked for 1 h at room temperature 
using 5% milk in TBST, then incubated with 1:10,000 dilution of HRP-conjugated anti-
MBP monoclonal antibody (NEB) for 1 h at room temperature. Membranes were 
developed using a chemiluminescent substrate (GE) and imaged using a Typhoon 
imager. 
We used a previously described spheroplast protection assay to assess 
membrane insertion and integration of MBP-containing chimeras (12). Briefly, cultures 
were processed using osmotic lysis (Epicenter Biotechnologies) to remove the outer 
membrane and isolate periplasts and spheroplasts. Spheroplasts were separated from 
periplasts by centrifugation (12,000 x g) for 5 min, and treated with proteinase K (to 
determine chimera orientation in theperiplasmic membrane) and Nonidet P-40 (to 
dissolve spheroplasts and release cytosolic proteins). Chimera expression levels in 
periplasts, spheroplasts, and cytosolic fractions were detected by immunoblotting as 
described above. 
 
 
2.2.5 Bioluminescence resonance energy transfer (BRET) 
 
8 µg of RAGE-GFP and -Rluc fusions were transfected into HEK293 cells by 
electroporation (GenePulser, Bio-Rad) using the HEK293 preset protocol in HEBS 
buffer (pH 7.05). Immediately after electroporation, cells were transferred to a white, 
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roundbottom 96 well plate (100 µl of cells per well) in DMEM containing 10% FBS 
with L -glutamine/VitaMax supplements and 1% Penn/Strep, and incubated at 37 °C 
and 5% CO2 for 48 h. Media was removed, cells were washed once with 100 µl of PBS 
per well before 100 µl of BRET buffer (0.1 g/liter CaCl2 , 0.1 g/liter MgCl2 , and 1 
g/liter D -glucose in PBS) was added to each well. 5 µl of Deep Blue C (GoldBio) was 
added to each sample well, and luminescence measurements (Filter 1: Green and Filter 
2: Magenta) were collected using a M200 Infinity plate reader (Tecan) over the course 
of the 10 s. The energy transfer efficiency is calculated by dividing the intensity of the 
signal for the green channel by the intensity of the signal for the magenta 
channel (21) in Equation 2.1. 
 
Energy Transfer Efficiency = (GFP Signal at 515 nm) / (Magenta Signal at 410 nm) 
(Eq. 2.1) 
 
The expression level of each eGFP2 -fused and Rluc-fused RAGE truncation was 
evaluated through Western blotting against anti-GFP and anti-Rluc antibody, 
respectively. Loading control was evaluated through Western blotting against 
antitubulin antibody and HEK293 cells expressing empty eGFP2 and Rluc vectors were 
used as negative control for BRET (Fig. 2.S1). 
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2.3 Results 
2.3.1 Design of AraTM assay 
 
The AraTM assay is based on transcriptional activity of the E. coli AraC 
transcription factor, which is active at the araBAD promoter as a homodimer (22). 
Wild-type AraC includes an N-terminal dimerization and ligand-binding domain (amino 
acids 1–87), which undergoes a conformational change upon L-arabinose binding to 
bind the I1 and I2 half-sites in the araBAD promoter, thereby driving gene expression 
(19). Genetic interaction studies indicate that replacement of the wild-type AraC 
dimerization domain with homo- and heterodimeric coiled-coils such as GCN4 and Fos-
Jun causes constitutive activation at the araBAD promoter, leading to the view that 
AraC is a modular transcriptional activator whose activity can be modified through 
controlling N-terminal domain dimerization (23, 24). We therefore modified wild-type 
AraC by replacing the N-terminal dimerization domain with receptor EX-TM-CYTO 
domains, and utilize GFP expression under control of the araBAD promoter as a 
measure of receptor domain dimerization. To ensure that EX-TM-CYTO fusions are 
properly integrated into the bacterial inner membrane, we generated chimeras that also 
contain an N-terminal fusion to full-length maltose-binding protein (MBP), including its 
native signal peptide sequence. MBP is a soluble, periplasmic protein responsible for 
high affinity binding and transport of maltose across the periplasmic membrane (25). 
Thus, full-length MBP directs the correct expression and integration of receptor EX-
TM-CYTO fusions into the periplasmic membrane through its native signal peptide 
sequence, thereby eliminating the need for the TM domain to act as a surrogate signal 
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peptide. Proper integration of MBP-EX-TM-CYTO-AraC chimera can be confirmed 
using both complementation experiments on growth media containing maltose as the 
sole carbon source as well as immunoblotting with anti-MBP antibodies (12). An 
overview of the AraTM assay is given in Fig. 2.2, and nucleic acid sequences for 
plasmids and primers used to develop the AraTM assay are provided in supplemental 
materials Section 2.6. 
  
Figure 2. 2. Overview of AraTM Assay. Chimeric proteins containing N-terminal 
MBPand C-terminal AraC domains fused with an in-frame receptor fragment are 
expressed by the regulator plasmid (pAraTM; kanamycin resistant). Once expressed, 
MBP directs expression of the chimera to the inner membrane of E. coli. 
Homodimerization brings AraC transcriptional factors in close proximity, enabling 
binding to the araBAD promoter on the reporter plasmid (pAraGFP; ampicillin 
resistance) and activating transcription of the reporter gene GFP.  
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2.3.2 Homodimerization of integrin αIIb TM-CYTO domains 
 
To confirm the AraTM assay is sensitive to specific residues known to be 
responsible for driving TM-CYTO domain dimerization, we used the TM-CYTO of 
human integrin αIIb as a model system (A963-E1008; Fig. 2.3A). Integrin αIIbβ3 is the 
major platelet receptor for fibrinogen, and is comprised of 2 type I integral membrane 
proteins that form a non-covalent heterodimer in the inactive state stabilized by both 
specific TM and CYTO interactions (3). Specifically, the integrin αIIb TM domain 
contains a conserved, GX3G motif that is important for homodimerization, which has 
led to a proposed push-pull mechanism for regulation of the inactive, active and 
clustered states in which the interplay between TM and CYTO interactions are 
important (4, 26, 27). For the wild-type integrin αIIb TM-CYTO (Figs. 2.3 and 2.4), 
significant homodimer formation occurs, with a GFP signal more than twice that of the 
negative control. Furthermore, when we introduce the specific TM mutation L980A into 
the TM-CYTO (A963-E1008), which was shown to substantially increase 
homooligomer formation measured using TOXCAT on a truncated TM construct 
(W968-K989) as well as by analytical ultracentrifugation and gel-shift assays on a 
purified TM-CYTO construct (A958-E1008), we observe a 1.5-fold increase in GFP 
signal relative to wild-type integrin αIIb TM-CYTO (Fig. 2.3, B and C) (6, 26). To 
correct for variation in homodimerization signal with cell density, results are reported as 
the slope of fluorescent intensity for GFP emission versus cell density for a series of 
cell dilutions. Both wild-type and L980A integrin αIIb TM-CYTO gives consistent 
results across several independent replicates at varying cell densities, with the majority 
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of individual measurements falling within the estimated 95% confidence interval for the 
entire dataset (Fig. 2.3B). We also quantified homodimerization of integrin αIIb TM-
CYTO constructs in individual cells using flow cytometry (Fig. 2.4). Compared with 
the wild-type integrin αIIb TM-CYTO, the constitutively active L980A mutant has a 
nearly 2-fold increase in GFP-positive cell population (Fig. 2.4, A and B), with a clear 
shift in the overall cell population to higher GFP expression levels rather than skew 
caused by a small subpopulation of highly fluorescent cells. Thus, the increase in 
dimerization observed for the L980A mutant reflects a true population average 
throughout the entire cell suspension. Furthermore, the magnitude of the increase in 
GFP fluorescence for wt versus L980A is similar for measurements using a micro- plate 
reader (Fig. 2.3) and flow cytometer (Fig. 2.4), which indicates the robustness of the 
AraTM method to multiple, independent methods for quantitation. 
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Figure 2. 3. AraTM Assay rRsults for Wild-type Integrin αIIb TM-CYTO and Its 
Mutations. A, integrin αIIb TM-CYTO sequence subcloned into pAraTM. The L980A 
mutation is also highlighted. B, fluorescence intensity at 530 nm of wild-type integrin 
αIIb TM-CYTO and mutant L980A from serial dilutions of bacterial cultures plotted 
against the corresponding cell density (OD600). Solid lines represent the best-fit line 
through the experimental data, and the dotted lines represent the upper and lower bound 
of the 95% confidence interval for each data set. C, average slopes from fluorescence 
intensity versus OD600 for each construct are compared from eight independent 
replicates, with error bars representing standard error. 
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Figure 2. 4. Population Distribution of GFP-positive Cells for Various Integrin αIIb 
AraTM Constructs by Flow Cytometry. A, compared with wild-type, the mutant L980A 
shows an increase in the % of total cell population (100,000 events) that is GFP-positive 
as well as a shift in the overall cell population measured in terms of FSC to a higher 
average GFP signal, which is in good agreement with whole-cell fluorescence 
measurements from cell suspension (Fig. 2.3). B, integrin αIIb L980A mutant shows a 2-
fold increase in the GFP-positive population as compared with wild-type. 
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Integrin αIIb wild-type and L980A TM-CYTO were both properly integrated in 
the E. coli inner membrane, as evidenced by growth on maltose M9 minimal plates 
(Fig. 2.5A), and expressed at similar levels, as confirmed by immunoblotting from 
whole-cell lysates (Fig. 2.5B). For integrin αIIb TM-CYTO mutant L980A, we also 
confirmed proper membrane integration and orientation using a modified spheroplast 
digestion assay described previously (12, 26). AraTM constructs were detected using an 
HRP-conjugated anti-MBP antibody. In particular, we observe intact chimera in the 
spheroplast fraction, but not the periplasmic or extracellular space, consistent with an 
inner membrane-integrated TM-CYTO chimera (Fig. 2.5C) rather than a secreted, 
soluble periplasmic TM-CYTO chimera. Furthermore, degradation of MBP by 
proteinase K treatment occurs in the spheroplast fraction in the absence of Nonidet P-40 
(Fig. 2.5C), which indicates the correct, N-terminal orientation of MBP in the 
periplasmic space accessible to proteinase K rather than accumulation of improperly 
trafficked chimera in the cytoplasmic space. If the MBP-TM-CYTO-AraC chimera was 
unable to integrate into the bacterial inner membrane, the membrane would act as a 
barrier to prevent degradation by proteinase K, resulting in detection of full-length 
chimera after proteinase K treatment of intact spheroplasts. Whereas in TOXCAT, the 
spheroplast prevents complete cleavage of MBP by proteinase K for properly integrated 
chimera (26), the addition of the flexible linker, including an HA epitope, between the 
N-terminal MBP and integrin αIIb TM-CYTO domain in AraTM increases proteinase K 
accessibility, which explains the loss of detectable chimera observed in intact 
spheroplasts by anti-MBP immunoblotting. In addition, for integrin αIIb TM-CYTO 
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L980A mutant, chimera expression begins after 3 h and remaining constant overnight as 
detected by immunoblotting from whole-cell lysates with anti-MBP antibody (Fig. 2.6). 
Thus, the AraTM assay is able to capture relative changes in homodimerization between 
wild-type integrin αIIb TM-CYTO (A963-E1008) and the key mutant L980A that has 
been show previously to cause constitutive activation in the full-length receptor (26). 
Furthermore, the AraTM assay is capable of properly integrating larger TM-CYTO 
fragments (A963-E1008; Fig. 2.3) into the bacterial inner membrane, in contrast to 
truncated TM domain fragments (W968-K989) used previously in TOXCAT (26). 
 
Figure 2. 5. The Integrin αIIb TM-CYTO Chimera Express at Similar Levels and Are 
Properly Integrated into the Inner Membrane of E. coli. A, AraTM chimeras containing 
wild-type and mutant integrin αIIb TM-CYTO expressed in MalE-deficient MM39 cells 
were streaked on a 0.4% maltose M9 plate and incubated for 48 h at 37 °C. Each 
construct is properly integrated into the inner membrane of E. coli, as indicated by 
robust growth on the 0.4% maltose M9 plates similar to the positive control (pTrcRSF 
containing MBP-AraC chimera). As expected, no growth is observed on the negative 
control (AraCY). B, wild-type and mutant integrin αIIb TM-CYTO chimera were 
expressed at equal levels as determined by immunoblotting with HRP-conjugated anti-
MBP antibody, and the observed chimera MWs were consistent with the expected 
MWs. C, periplasts and spheroplasts were prepared for mutant integrin αIIb L980A TM-
CYTO, treated with and without Nonidet P-40 (1% v/v) and proteinase K (50 µg/ml), 
and blotted against anti-MBP antibody (WC: whole cell, P: periplast, SP: spheroplast, 
SN: supernatant, PK: proteinase K, and Nonidet P-40: Detergent Nonidet P-40). No 
chimera is detected in intact spheroplasts treated with proteinase K (SP+PK) nor in the 
periplasmic fraction of the cell, consistent with the expected periplasmic orientation and 
membrane integration of the MBP fusion. 
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Figure 2. 6. Monitoring Expression of AraTM Chimera in Cell Culture. Cells 
expressing integrin αIIb L980A chimera were collected hourly to monitor expression 
level and degradation products by immunoblotting with an anti-MBP antibody. Chimera 
expression began 3 h post-induction at 37 °C and remained constant overnight. 
 
 
2.3.3 Identifying domains critical for homodimerization of RAGE 
 
RAGE is a 43 kDa type I TM receptor that belongs to the immunoglobulin 
superfamily (28). RAGE is expressed in a wide range of tissues, including brain, liver, 
and heart, where it activates pro-inflammatory signaling as part of the innate immune 
system in response to external stress (29). RAGEis capable of binding several ligands 
such as S100-family proteins, amyloid-β peptide and advanced glycation endproducts 
(AGE), and the binding of each ligand as well as subsequent signaling depends on the 
oligomeric state of the receptor (28, 30). RAGE exists in 2 major forms (Fig. 2.7A): a 
full-length, TM receptor (RAGE) as well as a soluble, extracellular domain (sRAGE) 
that acts as a dominant-negative to inhibit ligand-dependent signaling (28). Most work 
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has focused on determining the structural basis for dimerization of sRAGE, which 
includes the V-domain (Fig. 2.7) that is responsible for binding AGE, as well as the V-
C1-C2 domain fragment (Fig. 7) that is responsible for binding multimeric S100A-
family ligands (31, 32). However, much less is known about specific TM-CYTO 
interactions that occur in oligomeric states of RAGE. 
 
 
Figure 2. 7. RAGE. A, graphic illustration of domain structure in the full-length 
receptor, including the TM and CYTO regions. B, annotation of amino acid sequences 
in full-length RAGE corresponding to specific domains within the receptor. Sequences 
for the TM and CYTO region of RAGE are given, including positions (A375, P394) for 
specific truncations in the CYTO region (SP: signal peptide, V: V domain, C1: C1 
domain, C2: C2 domain, PR: proximal domain). 
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 We generated a series of RAGE domain deletions, including deletions of 
extracellular C2 and CYTO domains, and quantified their homodimerization using the 
AraTM assay. Domains and numbering used to delineate the specific domains with 
RAGE used are given in Fig. 2.7B. Full-length RAGE (V-C1-C2-PR-TM-CYTOfull; 
A23-P404) and RAGE chimera containing C1-domains (C1-C2-PR-TM-CYTOfull; 
P124-P404) were unable to complement grow on maltose minimal media, and were 
therefore excluded from further analysis (Fig. 2.8A). However, all other RAGE 
constructs were properly integrated into the bacterial inner membrane, as indicated by 
robust growth on maltose M9 minimal plates (Fig. 2.8A), and each was expressed at 
similar levels as indicated by whole-cell immunoblotting with anti-MBP (Fig. 2.8B). 
Isolation of spheroplasts from cells expressing RAGE PR-TM-CYTOfull (R314-P404) 
indicated they were properly oriented into the inner membrane (Fig. 2.8C), as 
degradation of MBP in intact spheroplasts occurred only after proteinase K treatment in 
the absence of Nonidet P-40 (12). We find that deletion of the C2 domain has little 
impact on homodimerization in constructs containing the CYTO domain (C2-PR-TM-
CYTOfull; P224-P404 and PR-TM-CYTOfull; R314-P404), whereas deletion of the 
CYTO domain significantly reduces homodimerization largely independent of the C2 
domain (C2-PR-TM; P224-R365 and PR-TM; R314-R365) (Fig. 2.9). We made 
additional deletions within RAGE CYTO to identify which regions were most 
important for homodimerization. We find that removal of the C-terminal distal region 
(PR-TM-CYTOP394; R314-P394) has no measurable impact on homodimerization, 
whereas deletion of the glutamic acid-rich region of the CYTO (PR-TM-CYTOA375; 
R314-A375) causes a modest decrease in homodimerization. However, deletion of the 
 40 
entire CYTO domain (PR-TM; R314-R365) causes a greater than 2-fold decrease in 
dimerization (Fig. 2.9), which indicates the juxtamembrane region (R365-A375) present 
within the CYTO is key for dimerization of TM RAGE constructs. Thus, we conclude 
that the RAGE CYTO exhibits strong homodimerization in the context of C2-TM-
CYTO domains expressed in cell membranes, particularly the juxtamembrane region 
(R365-A375) present within the CYTO. 
 
 
Figure 2. 8. Expression of RAGE constructs in AraTM assay. A, RAGE C2-PR-TM-
CYTOfull AraTM chimera as well as additional truncations of RAGE C2-PR-TM-
CYTOfull are able to complement growth on maltose M9 minimal plates. B, cells 
expressing RAGE chimera were expressed at similar levels and the chimera MWs are 
consistent with the expected MWs as determined by immunoblotting from whole-cell 
lysates with anti-MBP antibody. C, periplasts and spheroplasts of the RAGE PR-TM-
CYTOfull chimera were prepared, treated with/without Nonidet P-40 (1% v/v) and 
proteinase K (50 µg/ml), and blotted against anti-MBP antibody (WC: whole cell, P: 
periplast, SP: spheroplast, SN: supernatant, PK: proteinase K, and Nonidet P-40: 
detergent Nonidet P-40). No chimera is detected in intact spheroplasts treated with 
proteinase K (SP+PK) nor in the periplasmic fraction of the cell, consistent with the 
expected periplasmic orientation and membrane integration of the MBP-RAGE-AraC 
fusion. 
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2.3.4 Homodimerization of RAGE receptor expressed in mammalian membranes 
 
To confirm that our results from the AraTM assay are relevant in the context of 
full-length RAGE, we generated full-length RAGE and RAGE CYTO deletions as 
fusions with both eGFP2 and Rluc, co-expressed both eGFP2  and Rluc fusions in 
HEK293 cells, and measured the apparent interaction between each CYTO domain 
deletion using BRET (33, 34). The extent of energy transfer was calculated by dividing 
the green signal (515 nm) by the magenta signal (410 nm) as described previously (33). 
Expression levels for each construct as eGFP2 and Rluc fusions were similar among 
different truncations as determined by immunoblotting with specific antibodies 
(supplemental materials Fig. 2.10). Consistent with previous FRET measurements in 
transfected HEK293 cells (35), we find that full-length RAGE receptor exhibits a strong 
homodimeric signal in the absence of ligand (Fig. 2.11). Consistent with our AraTM 
results, removal of the C-terminal distal region (V-C1-C2-PR-TM-CYTOP394; A23-
P394) has no impact on homodimerization, but removal of the glutamic acid-rich 
CYTO region (V-C1-C2-PR-TM-CYTOA375; A23-A375) causes a significant decrease 
of nearly 25% in the measured BRET signal relative to wild-type RAGE (Fig. 2.11). It 
should be noted that the decrease in observed homodimerization for the V-C1-C2-PR-
TM-CYTOA375 construct measured using BRET (Fig. 2.11) is greater than the 
intermediate reduction in homodimerization signal measured using AraTM (Fig. 2.9), 
which indicates a significant, but intermediate effect on dimerization. Deletion of the 
CYTO reduces the measured BRET signal by 50% to near background levels. Thus, the 
trend in terms of reduction in homodimerization for the PR-TM-CYTO deletions 
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observed in AraTM (Fig. 2.9) are consistent with RAGE truncations expressed in 
HEK293 cells (Fig. 2.11), and the unliganded receptor is stabilized through interactions 
involving the juxtamembrane region of RAGE (R365-A375) present in the CYTO. 
 
Figure 2. 9. Cytoplasmic Truncations of RAGE Reduce Homodimerization in Cell 
Membranes. Removing the last 10 amino acids in the cytosolic domain of RAGE (PR-
TM-CTYOP394) had minimal affect on RAGE dimerization, whereas removal of the 
central domain (PR-TM-CYTOA375) reduced dimerization, but not to background 
levels observed in the cytoplasmic domain deletion construct. Results shown are from 
three independent replicates and the error bars represent standard error. 
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Figure 2. 10. Molecular weights for the expected products in each lane are provided at 
the bottom of the gel. A, HEK293 cells expressing various RAGE truncations fused to 
GFP were blotted against anti-GFP and anti-Rluc antibodies, and similar ratios of 
receptor expression are observed for both constructs. B, The same membrane probed 
with anti-GFP and anti-Rluc from A was blotted with an anti-tubulin antibody as a 
loading control to confirm similar levels of total sample per well. 
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Figure 2. 11. RAGE Domain Interactions in Mammalian Membranes Correlate with 
AraTM Results, and Highlight the Importance of Cytoplasmic Domain Interactions in 
Ligand-independent Dimerization. Significant dimerization of RAGE is observed in the 
absence of the ligand. Removal of the distal C-terminal region (P394) has no impact on 
homodimerization, but removal of the central CYTO region (A375) causes a significant 
decrease in homodimerization. Experiments were repeated three times in triplicate, and 
error bars represent stand error of the mean (Full: full-length, P394: CYTO truncation at 
P394, A375: CYTO truncation at A375, ΔCYTO: CYTO truncation, and Negative: 
negative control). 
 
 
2.4 Discussion 
 
The AraTM method provides several advantages in investigating the importance 
of extracellular (EX), transmembrane (TM), and cytoplasmic (CYTO) domains in 
defining the dimeric state of TM receptors. In particular, the C-terminal orientation of 
the DNA-binding domain in AraC enables expression of chimera, including both 
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soluble and transmembrane domains, as a fusion to full-length MBP, including its 
native signal peptide, to direct membrane insertion. As mentioned previously, the ToxR 
transcription factor used in TOXCAT, POSSYCAT and TOXluc assays is a type II 
integral membrane protein containing an N-terminal DNA-binding domain, in which 
the ToxR TM domain functions as a signal peptide to direct trafficking to the bacterial 
inner membrane as well as membrane integration of ToxR (17, 18). Thus, modifications 
to ToxR-TM-MBP chimera that include both soluble EX or CYTO domains fused to 
TM domains, or specific mutations within a given TM domain, can interfere with 
membrane trafficking and lead to large differences in chimera expression levels 
between different constructs (36). In contrast, the C-terminal orientation of the DNA-
binding domain in AraC enables expression of constructs in their native orientation, and 
utilizes the native signal peptide of MBP to direct insertion into the bacterial inner 
membrane (Figs. 2.1 and 2.2). Thus, the AraTM method decouples the dependence of a 
given TM construct on membrane trafficking from its dimerization in the bacterial inner 
membrane. This is particularly important given the large impact on extent of 
dimerization that can occur with cell-to-cell and construct-to-construct variability in 
ToxR-TM-MBP expression observed using TOXCAT, as well as the need to perform 
serial N- and C-terminal deletions of specific amino acids within a given TM domain to 
maximize membrane integration of expressed ToxR-TM-MBP chimera (12, 36). As 
illustrated for both integrin αIIb  (Fig. 2.5) and RAGE (Fig. 2.8), the AraTM system is 
robust to expression and proper membrane integration of a wide range of EX, TM, and 
CYTO constructs, including RAGE C2-PR-TM-CYTOfull (P224-P404, 21.3 kDa) and 
integrin αIIb TM-CYTO (A963-E1008; 5.2 kDa), versus truncated TM domains such as 
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that used in TOXCAT for integrin αIIb TM (W968-K989; 2.5 kDa) (26). Thus, the 
AraTM method (Fig. 2.2) enables analysis of dimerization in cell membranes of multi-
domain receptor chimera that include EX, TM2 and CYTO, which is of particular use in 
investigating juxtamembrane interactions important in defining active and inactive 
states during signal transduction (6, 8–10). 
 The use of eGFP as a reporter gene in AraTM also allows for assays to be 
performed directly from cell culture using a microplate reader or flow cytometer, 
without a need for cell lysis, sample preparation or addition of exogenous substrates 
required for other common reporters such as CAT or luciferase. As mentioned before, 
cell-to-cell variability in TOXCAT chimera expression levels has a major impact on the 
observed dimerization signal (36), which we can measure directly from whole cells 
using flow cytometry to determine average dimerization per cell for a statistically 
significant sample size ( >106  cells; Fig. 2.4). As illustrated by our measurements using 
integrin αIIb TM-CYTO (A693-E1008), the AraTM method is sensitive to specific point 
mutations in the context of multidomain constructs, with a significant increase in 
homodimerization observed in the case of the TM L980A mutant relative to wt TM-
CYTO (Fig. 2.4) (4, 26). Furthermore, the quantitative agreement between the relative 
increase in dimerization for wt integrin αIIb TM-CYTO and L980A mutant measured 
using a microplate fluorescence plate reader (Fig. 2.3) and flow cytometer (Fig. 2.4), as 
well as the shift in total population mean observed between wt and L980A (Fig. 2.4), 
indicate the increase in observed GFP signal for L980A is due to a uniform increase in 
dimerization across the entire cell population rather than skew in the distribution caused 
by a specific cell subpopulation. Thus, the AraTM method is able to capture effects of 
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specific mutations on homodimerization in the context of TM-CYTO receptor 
fragments that are consistent with results from previously described in vitro  and cell-
based assays for integrin αIIb. 
 In addition, our results point to a direct role for the RAGE CYTO in stabilizing 
the homooligomeric, unliganded form of the receptor. Previous studies have focused on 
the soluble, extracellular form of RAGE (sRAGE) containing the V-, C1-, and C2-
domains as the primary driving force for homodimerization (31, 32). Purified sRAGE 
and C1-C2 domains assemble to form stable tetramers in vitro, and upon hexameric 
calgranulin binding, sRAGE undergoes significant conformational rearrangement in the 
ectodomain to form higher-order oligomers in the soluble, liganded state (32). 
Overexpression of full-length RAGE in transfected mammalian cells as mCFP and 
mYFP fusions result in significant co-localization and FRET transfer efficiency at the 
surface of transfected HEK293 cells, which supports the idea of RAGE exists in a 
homooligomeric state in the absence of ligand (35). Using AraTM, we find that the C2 
domain does not play a key role in EX-TM-CYTO homodimerization, whereas the 
CYTO domain plays a key role in stabilizing the unliganded, homodimeric state of 
RAGE (Fig. 2.9). Specifically, deletion of the distal C-terminal region (PR-TM-
CYTOP394; R314-P394) has no impact on dimerization, whereas deletion of the central 
cytoplasmic domain (PR-TM-CYTOA375; R314-A375) significantly reduces RAGE 
homodimerization, and the cytoplasmic domain deletion eliminated homodimerization. 
Previous work has indicated the extracellular V- and C1-domains as critical for 
dimerization of sRAGE in the absence of ligand (31, 32), whereas our BRET results for 
full-length RAGE indicate the strong self-association propensity of the CYTO domain 
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in stabilizing the resting state of the receptor, specifically the juxtamembrane region 
(A375-P394) within the CYTO important for stabilization of the unliganded, 
homodimeric state (Fig. 10). Recent NMR data investigating RAGE CYTO binding to 
the cytosolic signaling protein mDia1 suggests that the TM-proximal region is 
important for protein-protein interactions involving cytosolic signaling molecules, with 
the R365-P376 region of the CYTO forming a stable α-turn in solution (37). Our 
AraTM (Fig. 2.9) and BRET (Fig. 2.10) results indicate this region may also play a key 
role in homodimerization in the unliganded state. Interestingly, there are multiple, 
conserved families of primarily soluble proteins containing glutamic acid rich regions, 
in which the glutamic acid-rich region is found to have important roles in protein 
structure and complex formation. Specifically, in the case of the soluble protein 
SH3BGR, the C-terminal, glutamic acid-rich region is predicted to adopt coiled-coil 
like structures capable of mediating protein-protein interactions (38). Other studies have 
suggested glutamic acid-rich regions may act as low-affinity, calcium-binding domains 
important in regulating local calcium concentrations (39). Thus, the disordered, 
glutamic acid  region of the CYTO observed previously by NMR may reflect one of 
several conformations for the RAGE CYTO during signal transduction (37). 
Furthermore, the overall correlation between the magnitude of homooligomerization 
measured using AraTM (Fig. 2.9) and BRET (Fig. 2.10) emphasizes the utility of the 
AraTM method to investigate the role of receptor dimerization in the biologically 
relevant context of cell membranes. 
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2.5 Conclusion 
 
 Overall, given the good agreement between our results for integrin αIIb and 
previously published results investigating homodimerization in vivo and in vitro, as well 
as the correlation between our results investigating RAGE domain homodimerization in 
bacterial membranes and BRET signal in transfected mammalian cells, the AraTM 
provides a useful, complementary method to other mammalian cell-based measurement 
techniques such as BRET and bacterial 2-hybrid assays such as BACTH to rapidly 
assess the importance of specific interfaces and domains within transmembrane 
receptors in defining their dimeric states (33, 40). 
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Chapter 3 
A NOVEL ASSAY FOR ASSESSING JUXTAMEMBRANE AND  
TRANSMEMBRANE DOMAIN INTERACTIONS IMPORTANT  
FOR RECEPTOR HETERODIMERIZATION 
 
The work described in this chapter has been published in “A Novel Assay for Assessing 
Juxtamembrane and Transmembrane Domain Interactions Important for Receptor 
Heterodimerzation” by Pin-Chuan Su and Bryan W. Berger, The Journal of 
Molecular Biology 2013 425 4652-4658. 
 
 
 
Understanding the basis of specificity in receptor homodimerization versus  
heterodimerization is essential in determining the role receptor plays in signal 
transduction. Specificity in each of the interfaces formed during signal transduction 
involves cooperative interactions between receptor extracellular, transmembrane (TM), 
and cytoplasmic domains. While methods exist for studying receptor heterodimerization 
in cell membranes, they are limited to either TM domains expressed in an inverted 
orientation or capture only heterodimerization in a single assay. To address this 
limitation, we have developed an assay (DN-AraTM) that enables simultaneous 
measurement of homodimerization and heterodimerization of type I receptor domains in 
their native orientation, including both soluble and TM domains. Using integrin αIIb and 
RAGE (receptor for a dvanced glycation endproducts) as model type I receptor systems, 
we demonstrate both specificity and sensitivity of our approach, which will provide a 
novel tool to identify specific domain interactions that are important in regulating 
signal transduction. 
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3.1 Introduction 
 
Receptor homodimerization and heterodimerization is a key mechanism that 
regulates transmembrane (TM) signal transduction (1). Several classes of type I TM 
receptors, including neuropilins and integrins, all exist in a regulated equilibrium 
between homodimeric and heterodimeric states, with each state defining the inactive or 
activated forms of the co-receptor complex (2,3). Furthermore, for both integrins and 
neuropilins, specific, cooperative interactions involving the TM, cytosolic [cytoplasmic 
(CYTO)], and juxtamembrane [extracellular (EX)] domains are critical in stabilizing the 
homodimeric and the heterodimeric states of the co-receptor complex. In the case of 
integrin αIIbβ3, the inactive, heterodimeric state is stabilized through a TM reciprocal “ 
large-small”  helical packing interface and a cytosolic clasp formed by an Arg-Asp salt 
bridge (4,5). Disruption of the cytosolic clasp by intracellular binding of talin to β3 or 
mutations to residues in the TM heterodimer interface triggers a series of 
conformational changes that lead to integrin activation and fibrinogen binding (6,7). 
Within the TM domain, activation can involve mutations to integrin αIIb or β3 that 
promote preferential TM homodimer formation, as well as mutations to either αIIb or β3 
that destabilize the heterodimeric interface (3). Thus, characterizing the interplay 
between specific, homodimeric and heterodimeric interactions involving TM and 
juxtamembrane (CYTO and EX) domains is essential in understanding the basis for TM 
signal transduction. 
 Among the methods available to characterize type I receptor heterodimerization 
in cell membranes, Escherichia coli-based transcription factor assays GALLEX and 
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DN-ToxRed have the advantage of straightforward implementation, high sensitivity, 
and rapid quantification of homodimerization and heterodimerization in terms of 
reporter gene expression levels such as red fluorescent protein (4,8,9). In the case of 
TOXCAT, extension of this method to polytopic membrane proteins has also been 
described (10). However, both assays rely on transcription factors (LexA for GALLEX 
and ToxR for DN-ToxRed) that have a type II orientation, in which the N-terminal 
DNA-binding domain is expressed as a fusion to a C-terminal TM domain of interest. 
Thus, the C-terminal TM domain acts as a signal peptide to direct membrane trafficking 
and integration, and any modification of the TM domain, including addition of CYTO 
and EX domains, can prevent proper membrane integration. As a result, bacterial 
heterodimerization assays GALLEX and DN-ToxRed are limited to analysis of only 
isolated TM domains. Likewise, while split-enzyme assays such as BACTH based on 
reconstitution of split adenylyl cyclase are effective in determining heterodimerization 
of a given receptor domain, they do not capture the simultaneous competition between 
homodimerization and heterodimerization often observed for full-length receptors 
during signal transduction (11). 
 To address the limitation of current bacterial heterodimerization assays, we 
developed a dominant-negative assay (DN-AraTM) to investigate type I receptor 
heterodimerization (Fig. 3.1). In DN-AraTM, a chimera containing wild-type AraC is 
co-expressed with a chimera that contains a non-functional, mutant AraC (AraC*) that 
is unable to activate gene transcription. Preferential heterodimerization (AraC-AraC*) 
reduces the level of green fluorescent protein (GFP) reporter gene transcription (under 
control of the araBAD promoter) relative to homodimerization (AraC-AraC), thereby 
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giving a quantitative measure of heterodimerization relative to homodimerization that 
can be measured directly in whole cells. As with AraTM, each chimera contains an N-
terminal maltose-binding protein (MBP) fusion that includes a signal peptide to direct 
membrane insertion, thereby enabling expression of receptor domains that include EX, 
TM, and CYTO domains (12). To confirm that both chimera are expressed in cell 
membranes, we introduce a unique HA or myc epitope into each chimera, allowing for 
quantification of expression levels by Western blotting using either unique HA or myc 
epitopes or MBP. We illustrate the effectiveness of DN-AraTM using integrin αIIb  and 
RAGE (receptor for a dvanced glycation endproducts) as model type I receptor systems. 
Collectively, our results indicate that DN-AraTM is robust to systems that exhibit 
preferential homodimerization and heterodimerization and provides a unique method to 
investigate the structural basis for domain interactions important in the regulation of 
type I receptor signal transduction. 
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Figure 3. 1. Overview of DN-AraTM Assay. Chimera containing N-terminal MBP 
fused to either an in-frame receptor A fragment (DOMAIN A) and C-terminal AraC or 
an in-frame receptor B fragment (DOMAIN B) and C-terminal disabled AraC unable to 
activate transcription at the araBAD promoter (AraC*) are expressed by the regulator 
plasmids (pAraTMwt, ampicillin resistant; pAraTMDN, kanamycin resistant). Once 
expressed, MBP directs integration of chimera in the inner membrane of E. coli. 
Homodimerization of receptor A (AraC-AraC) brings the AraC transcription factors in 
close proximity and activates the araBAD promoter to produce GFP. If receptor A has a 
higher affinity to heterodimerize with receptor B versus homodimerize with receptor A, 
a reduction in GFP will be observed (AraC-AraC*) due to the inability of heterodimers 
containing receptor B-fused AraC* to activate transcription at the araBAD promoter. 
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3.2 Materials and Methods 
3.2.1 Subcloning 
 
Unless otherwise stated, standard molecular biology techniques were used. All 
constructs used were verified by DNA sequencing. An overview of the DN-AraTM 
assay is given in Fig. 3.1. Plasmid pAraTM was generated as described previously (12). 
Plasmid pAraTMmyc was generated by amplifying the MBP sequence from the 
pAraTM plasmid with primers that introduce a C-terminal myc-tag sequence 
(EQKLISEEDL). The resulting PCR product was subcloned into the pAraTM plasmid 
as an NcoI/SacI fragment.  
pAraTMDN plasmid was generated by making a point mutation R210A in the 
truncated AraCamino acid sequence (amino acids 168–293) in the pAraTMmyc plasmid 
using the QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies) to 
generate a dominant-negative form of AraC (AraC*). The truncated AraC amino acid 
sequence (amino acids 168–293) lacks its N-terminal dimerization domain, which is 
instead replaced with the receptor domain of interested to promote AraC dimerization. 
The pAraTMDN plasmid was used for all subsequent experiments, with RAGE and 
integrin αIIb domains cloned in-frame as fusions with MBP and AraC* as SacI/KpnI 
fragments. 
Plasmid pAraTMwt was generated by amplifying the MBP-HA-MCS-AraC 
(amino acids 168–293) from the pAraTM plasmid and subcloning into pTrc99a as an 
NcoI/HindIII fragment. The pAraTMwt plasmid was used for all subsequent 
experiments, with RAGE and integrin αIIb domains cloned in-frame as fusions with 
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MBP and AraC as SacI/KpnI fragments. Note that the LacI gene on the pAraTMwt 
allows IPTG-regulated expression of both AraC and AraC* chimera; for all 
experiments, 1 mM IPTG was added to culture. 
The reporter plasmid pAraGFPCDF was derived from plasmid pAraGFP by 
amplifying a fragment containing the araBAD promoter and GFP coding sequence and 
subcloning into a pCDFDuet-1 plasmid (Novagen) as an EcoRI/PstI fragment. 
 
    
3.2.2 DN-AraTM assay 
 
Plasmids pAraTMDN, pAraTMwt, and pAraGFPCDF were co-transformed into 
the AraC-deficient E. coli strain SB1676 (The E. coli Genetic Stock Center at Yale 
University) and streaked on selective LB plates (100 µg/mL ampicillin, 50 µg/mL 
kanamycin, and 100 µg/mL spectinomycin). One colony was picked from each 
construct and grown in 4 mL selective LB media for 16 h at 37 °C and 200 rpm. After 
16 h, the cultures were diluted to A560 of 0.5 in three wells on a 2.0-mL-deep, 96-well 
PP plate (PlateOne) with each well containing 400 µL of selective LB media (100 
µg/mL ampicillin, 50 µg/mL kanamycin, 100 µg/mL spectinomycin, and 1 mM IPTG) 
and grown for an additional 6 h at 37 °C and 300 rpm. We transferred 200 µL of 
cultures from each sample to a black 96-well, clear bottom plate (Greiner) and a series 
of 2-fold dilutions was prepared using selective LB media. A560 measurements and 
GFP fluorescence emissions spectra (excitation maximumat 485 nm and emissions 
maximum at 530 nm) were collected using an M200 Infinity Plate Reader (Tecan). 
Results are reported as the ratio of fluorescence emission at 530 nm to absorbance at 
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560 nm and normalized to the negative control (pAraGFPCDF, pTrc99a, and pTrcRSF 
transformed cells), where the results were first divided by the negative control ratio and 
rescaled so that the negative control is equal to zero. 
 
3.2.3 Proper integration of AraC chimera into the inner membrane of E. coli and 
immunoblotting  
 
The maltose complementation test was carried out as described previously to 
demonstrate the proper integration of AraC chimera into the inner membrane of E. coli 
(12). Immunoblotting was carried out as described previously to demonstrate proper 
expression of each full-length AraC chimera using anti-myc (Cell Signaling) and anti-
HA (Cell Signaling) monoclonal antibodies (12). 
 
 
3.3 Results 
 
3.3.1 Design of DN-araTM heterodimer assay 
 
The DN-AraTM assay is a dominant-negative system based on the E. coli 
transcription factor AraC, which is active at the araBAD promoter as a homodimer (13). 
The overall process is illustrated in Fig. 3.1, where a wild-type AraC chimera (AraC) is 
co-expressed with a AraC chimera in which a point mutation in the DNA-binding 
domain of AraC (R210A) was introduced to inactivate transcription (AraC*). We 
screened a series of previously described inactivating mutations in the DNA-binding 
domain of AraC (H203A, R210A, and R216A) and found that, of these, R210A 
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exhibited reproducibly minimumactivity at the araBAD promoter when expressed as 
part of a TM domain-containing chimera (Fig. 3.2) (14). As with AraTM, both chimera 
also contain an N-terminal MBP fusion with signal peptide to direct integration into the 
inner E. coli membrane, thereby enabling expression of type I receptors including EX, 
TM, and CYTO domains in their native orientation (12). When chimera containing 
AraC and AraC* are each co-expressed from unique plasmids (pAraTMwt and 
pAraTMDN) and properly integrated into the inner membrane, the AraC*-containing 
chimera acts as a dominant negative (DN) to inhibit the homodimerization of the AraC-
containing chimera, thereby reducing the transcriptional activity at the araBAD 
promoter due to formation of AraC-AraC* heterodimeric complexes. In this way, the 
relative decrease in expression of the reporter gene GFP for a heterodimeric competitor 
involving two unique receptor sequences (A-B*) relative to a homodimeric sequence 
(A-A) provides a quantitative measure of preferential receptor heterodimerization. If the 
reduction in signal for the heterodimer (A-B*) is more than that for the respective 
homodimer (A-A), then the two receptor domains (A and B) form a preferential 
heterodimer, with the strength of the relative heterodimer quantified in terms of 
difference in signal between A-A and A-B*. 
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Figure 3. 2. Dominant-negative Form of AraC (R210A) Disrupts Its Ability to Turn on 
araBAD Promoter. A, The R210A mutation in the DNA binding domain of AraC 
eliminates the ability of chimera containing wild-type integrin αIIb TM-CYTO AraC to 
activate GFP transcription at the araBAD promoter. Experiments were repeated three 
times in triplicate, and error bars represent standard deviation. B, The expression level 
of AraC and AraC* chimera containing wild-type integrin αIIb TM-CYTO are similar 
as shown by immunoblotting with anti-MBP antibody from whole-cell lysates (WT: 
wild-type AraC chimera, H203A: H203A mutant AraC chimera, R210A: R210A mutant 
AraC chimera, and R216A: R216A mutant AraC chimera). 
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3.3.2 Multiple epitope tags to confirm heterodimer expression 
 
Unlike AraTM, in which a single receptor is expressed to measure homodimer 
formation, in DN-AraTM, two independent receptor domains are co-expressed, with the 
relative competition between homodimer and heterodimer formation measured (Fig. 
3.1). Thus, it is important to ensure that expression levels of both AraC and competitor 
AraC* fusions are similar in order to have an accurate measure of homodimer versus 
heterodimer formation. To address this issue, we replaced the HA-tag on the 
pAraTMDN plasmid with a myc-tag; thus, AraC chimera expressed by the pAraTMwt 
can be detected with an anti-HA antibody and AraC* chimera expressed by pAraTMDN 
can be detected with an anti-myc antibody. Additionally, we can utilize an anti-MBP 
antibody to compare expression levels for co-expression of both AraC and AraC* 
chimera versus expression of either AraC or AraC* chimera alone. 
First, to confirm that the epitope used has no effect on chimera orientation or 
expression in the E. coli inner membrane, we replaced the HA-tag on the pAraTM 
plasmid by a myc-tag to make pAraTMmyc plasmid and we compared GFP reporter 
gene expression from integrin αIIb L980A TM-CYTO for both chimera; this construct 
was used previously as a model homodimer for AraTM (12). After expression in E. coli, 
both constructs could activate transcription at the araBAD promoter, resulting in similar 
GFP reporter gene expression levels (Fig. 3.3B), indicating that the myc-tag did not 
significantly alter AraC transcriptional activity relative to the HA-tag used previously in 
AraTM (12). Both chimera expressed by pAraTMmyc and pAraTM can properly 
integrate into the E. coli inner membrane as demonstrated by growth on maltose 
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minimal media plates (Fig. 3.3C). Moreover, immunoblotting whole-cell lysates from 
integrin αIIb L980A TM-CYTO expressed from pAra-TMmyc and pAraTM with anti-
myc and anti-HA, respectively, indicate that both fusion tags were expressed and can be 
recognized by the antibodies. Independent of HA and myc epitopes, immunoblotting 
whole-cell lysates against anti-MBP antibody confirmed both constructs expressed at 
similar levels (Fig. 3.3D). Thus, we have two independent methods to confirm 
expression of AraC- and AraC*-containing chimera: (1) intensity of total anti-MBP 
signal for total AraC and AraC* chimera and (2) comparison of anti-myc and anti-HA 
signal specific to either AraC or AraC* chimera. 
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Figure 3. 3. AraTM Chimera Containing Either an HA-tag and a Myc-tag Are 
Expressed and Integrated Correctly into E. coli Inner Membrane, and Both Chimera 
Retain Proper AraC Transcriptional Activity. A, Amino acid sequence of integrin αIIb 
TM-CYTO and the position of L980A mutation. B, AraTM chimera with the 
homodimeric integrin αIIb L980A TM-CYTO construct that contain either an HA-tag 
or a myc-tag exhibit comparable AraC transcriptional activity. C, AraTM chimera with 
the homodimeric integrin αIIb L980A TM-CYTO construct that contain either an HA-
tag or a myc-tag were expressed from plasmid pAraTM or pAraTMmyc in MBP-
deficient MM39 cells, streaked onto a 0.4% maltose M9 plate and incubated for 40 h at 
37 °C. Both HA-tagged and myc-tagged constructs are properly integrated into the inner 
membrane of E. coli as evidenced by robust growth similar to the positive control 
(pTrcRSF containing MBP-AraC chimera). As expected, no growth is observed on the 
negative control (AraCY, which expresses MBP without the N-terminal signal peptide 
sequence fused to AraC protein). D, Immunoblotting of whole-cell lysate with anti-myc, 
anti-HA, and anti-MBP antibodies indicate that both chimera are expressed at their 
expected molecular masses (64 kDa). 
 
 
3.3.3 Heterodimerization of integrin αIIb and RAGE TM-CYTO domains 
 
To confirm DN-AraTM is sensitive to heterodimer formation, we used the TM-
CYTO of human integrin αIIb  (residues A963-E1008) and its dimer-forming TM mutant 
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L980A as a model system (15). Previous studies have shown that human integrin αIIb  
TM domain forms a homodimer through a conserved GX3G motif, and the L980A 
mutant enhances homodimer formation by placing an additional small residue, alanine, 
on the same face of the TM helix as the conserved GX3G (16). When αIIb L980A is 
expressed as a fusion to wild-type AraC, a strong homodimer signal is observed, with a 
GFP signal 4-fold higher than the negative control, which expresses the reporter 
plasmid pAraGFPCDF with empty pTrc99a and pTrcRSF (Fig. 3.4). Likewise, when 
αIIb L980A-AraC* is co-expressed as a competitor to αIIb L980A-AraC, a significant 
decrease in GFP expression is observed, again consistent with the strong homodimer 
forming tendency of αIIb L980A (Fig. 3.4). However, when αIIb wild-type AraC* is co-
expressed as a competitor to αIIb L980A-AraC, no significant decrease in GFP 
expression is observed relative to the αIIb L980A-AraC homodimer, again consistent 
with the expected result that αIIb L980A forms a strong, preferential homodimer (large 
decrease in GFP signal in DN-AraTM) versus an αIIb L980A-αIIb wild-type heterodimer 
(no decrease in GFP signal in DN-AraTM). Integrin αIIb wild-type and αIIb L980A TM-
CYTO constructs were both expressed and properly integrated in the E. coli membrane, 
as evidenced by growth on maltose M9 minimal plates (Fig. 3.5) for both AraC- and 
AraC*-containing chimera. When expressed individually, pAraTMwt and pAraTMDN 
chimera had similar immunoblotting band intensities (Fig. 3.5), and the intensity 
doubled when both chimera were co-expressed (Fig. 3.5), indicating that both chimera 
are expressed at similar levels. 
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Figure 3. 4. Quantifying Receptor Homodimerization and Heterodimerization using the 
DN-AraTM Assay. Significant heterodimerization is observed for AraC*-integrin 
αIIbL980A TM-CYTO as competitor to AraC-integrin αIIb L980A TM-CYTO, but not 
with AraC*-wild-type integrin αIIb TM-CYTO as competitor. The sequences for integrin 
αIIb wild-type and L980A TM-CYTO are given for reference. Thus, the strong AraC-
AraC* heterodimer formed from integrin αIIb L980A TM-CYTO gives rise to a 
reduction in overall GFP expression indicative of heterodimerization, whereas the 
strong AraC-AraC homodimer formed from integrin αIIb L980A TM-CYTO is not 
destabilized by the AraC*-integrin αIIb wild-type TM-CYTO, therefore indicative of 
preferential homodimerization by retaining high GFP expression. Each measurement is 
from three independent replicates, with error bars representing standard deviation. 
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Figure 3. 5. AraC* chimera were properly expressed and integrated into the bacterial 
inner membrane. A, Summary of plasmid combinations used in co-expression 
experiments. B, Immunoblotting of whole cell lysate from each sample with anti-MBP 
antibody indicates proper expression of homo- and heterodimeric chimera, with the 
intensity of the bands for co-expression of both AraC- and AraC*-containing chimera 
twice that of the corresponding bands for single chimera expression. C, Chimera 
containing AraC* fused to wild-type and L980A integrin αIIb TM-CYTO were 
expressed in MalE-deficient MM39 cells, streaked on a 0.4% maltose M9 plate and 
incubated for 40 h at 37°C. Each construct was properly integrated into the inner 
membrane of E. coli, as indicated by robust growth on the 0.4% maltose M9 plate 
similar to the positive control (pAraTM containing integrin αIIb TM-CYTO chimera 
fused to AraC and MBP-HA) As expected, no growth is observed on the negative 
control (AraCY, which expresses MBP without the N-terminal signal peptide sequence 
fused to AraC protein). 
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 In addition to integrin αIIb TM-CYTO, we also investigated whether co-
expression of RAGE TM-CYTO as an AraC* fusion could inhibit RAGE homodimer 
formation (Fig. 3.6). RAGE is a type I TM receptor whose dimeric and higher-order 
oligomeric state is important in determining the specificity of EX ligand binding (17). 
In particular, RAGE exists in an unliganded state as a dimer, and the EX domain forms 
tetramers and octamers when bound to the ligands S100A12 and S100B (18,19). Our 
previous work indicates that the unliganded RAGE homodimer also depends on the 
cytosolic region of the receptor, specifically the juxtamembrane region enriched in 
glutamic acids to promote homodimer formation (12). Thus, the RAGE TM-CYTO 
provides a useful, complementary system to integrin αIIb to assess the sensitivity of the 
DN-AraTM assay. When RAGE TM-CYTO-AraC* is co-expressed as a competitor to 
RAGE TM-CYTO-AraC, a significant decrease in GFP expression is observed relative 
to the corresponding RAGE TM-CYTO-AraC homodimer (Fig. 3.6). This further 
demonstrates the ability of DN-AraTM assay to assess receptor domain 
heterodimerization. 
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Figure 3. 6. Effectiveness of Heterodimeric AraTM Assay was Demonstrated by 
Competing Wild-type and R210A AraC Fused RAGE PR-TM-CYTOfull Chimera. A, 
Summary of plasmid combinations used in co-expression experiments. B, The average 
slopes from 2 fluorescence intensity versus OD600 for each construct are compared from 
three independent replicates, with error bars representing standard deviation. When 
chimera containing AraC fused to RAGE PR-TM-CYTO are co-expressed with AraC* 
chimera containing RAGE PR-TM-CYTO, a significant decrease in GFP was observed 
as a result of strong homo- and heterodimerization, consistent with previous results 
indicating RAGE PR-TM-CYTO forms a strong homodimer (11). C, Immunoblotting of 
whole cell lysate from each sample with anti-MBP antibody confirm co-expression of 
chimera, as indicated by the increase in intensity of the anti-MBP signal for AraC- and 
AraC* heterodimer co-expression relative to the AraC homodimer alone sample. D, 
AraTM chimera containing AraC* fused to RAGE PR-TM-CYTO were expressed in 
MalE-deficient MM39 cells, streaked on a 0.4% maltose M9 plate and incubated for 40 
h at 37°C. AraC* fused RAGE PR-TM-CYTO chimera is properly integrated into the 
inner membrane of E. coli, as indicated by robust growth on the 0.4% maltose M9 plate. 
As expected, no growth is observed on the negative control (AraCY, which expresses 
MBP without the Nterminal signal peptide sequence fused to AraC protein). 
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3.4 Discussion 
 
The DN-AraTM assay provides several advantages in investigating the 
importance of EX, TM, and CYTO domains in defining the heterodimeric state of type I 
TM receptors. First, the C-terminal orientation of the DNA-binding domain in AraC 
enables expression of receptor chimera, including both soluble (EX and CYTO) and 
TM domains, as a fusion to full-length MBP including its native signal peptide. The N-
terminal MBP with signal peptide enables expression of type I receptors in their native 
orientation and proper trafficking to the bacterial inner membrane, unlike ToxR-based 
(DN-ToxRed) or LexA-based (GALLEX) transcriptional assays in which a type II 
orientation is required (4,8,9). For type II orientations, the TM domain acts both as the 
dimerization domain of interest and as the signal peptide to direct protein trafficking to 
the membrane (20). Thus, modifications to the TM domain of interest, including 
addition of EX or CYTO domains, can impair membrane trafficking for both DN-
ToxRed and GALLEX, unlike the DN-AraTM assay. Given the importance of 
cooperative interactions between TM and soluble (EX and CYTO) regions in stabilizing 
receptor heterodimers such as integrins, this is a significant advantage when 
understanding the underlying structural basis for heterodimerization (5,6,15,16). 
In addition, the DN-AraTM assay provides a method to quantify the equilibrium 
between homodimerization and heterodimerization. Most receptors exist in a regulated 
equilibrium between homodimeric and heterodimeric states, with each corresponding to 
the biologically relevant resting or activated state during signal transduction (1). The 
DN-AraTM assay allows monitoring of the homodimeric state of a given receptor as an 
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AraC fusion, and through competition with a non-functional AraC fusion (AraC*), the 
relative decrease in homodimerization due to heterodimer formation can be compared 
(Fig. 3.1). Since the DN-AraTM assay depends on the reduction in reporter gene signal 
to quantify heterodimer formation, it is also important to have a sensitive reporter such 
as GFP that can be detected directly with a high degree of sensitivity from whole cells. 
As illustrated for both integrin αIIb and RAGE receptor (Fig. 3.4 and Fig. 3.6), the DN-
AraTM assay is robust to specific interactions between TM domains that exhibit 
preferential homodimers and heterodimers. 
 
3.5 Conclusion 
 
 Overall, given the good agreement between the observed and expected results 
for the integrin αIIb heterodimer competition experiments (Fig. 3.4) and the ability to 
assay expression level of each AraC chimera (Fig. 3.2), the AraTM heterodimeric assay 
provides a useful, complementary method to access important specific interfaces and 
domains within TM domains of proteins in defining receptor heterodimerization. We 
feel that DN-AraTM will provide a useful, complementary technique to mammalian 
cell-based BRET and bacterial two-hybrid BACTH system in investigating the 
importance of receptor TM and juxtamembrane domain interactions in regulating signal 
transduction (11,21). 
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Chapter 4 
HIGH-YIELD MEMBRANE PROTEIN EXPRESSION FROM E.   
COLI USING AN ENGINEERED OUTER MEMBRANE PROTEIN  
F FUSION 
 
The work described in this chapter has been published in “High-yield Membrane  
Protein Expression from E. coli Using an Engineered Outer Membrane Protein F  
Fusion” by Pin-Chuan Su, William Si, Deidre L. Baker, and Bryan W. Berger, Protein  
Science 2013 22 435-443. 
 
 
Obtaining high yields of membrane proteins necessary to perform detailed 
structural study is difficult due to poor solubility and variability in yields from 
heterologous expression systems. To address this issue, an Escherichia coli-based 
membrane protein overexpression system utilizing an engineered bacterial outer 
membrane protein F (pOmpF) fusion has been developed. Full-length human receptor 
activity-modifying protein 1 (RAMP1) was expressed using pOmpF, solubilized in FC15 
and purified to homogeneity. Using circular dichroism and fluorescence spectroscopy, 
purified full-length RAMP1 is composed of approximately 90% a-helix, and retains its 
solubility and structure in FC15 over a wide range of temperatures (20–60°C). Thus, 
our approach provides a useful, complementary approach to achieve high-yield, full-
length membrane protein overexpression for biophysical studies. 
 
4.1 Introduction 
 
Membrane receptors play a significant role in regulating numerous fundamental 
biological processes, including membrane trafficking, signal transduction, and cell–cell 
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communication (1). Thus, it is estimated that 20–30% of all predicted proteins in 
sequenced genomes encode for integral membrane proteins (2). Despite their prevalence 
and numerous important biological roles, the number of integral membrane protein 
high-resolution structures available in the protein data bank (PDB) is <1% (3). The 
challenges in solving membrane protein structures are many, including their insolubility 
in aqueous solutions and low abundance in their native membrane environment. Thus, 
obtaining the high yields of homogeneous, soluble membrane protein required for 
detailed structural studies is a major challenge (4–6). 
 Numerous approaches have been developed to improve the yield and recovery 
of integral membrane proteins. Among the most popular methods for largescale, 
Recombinant membrane protein expression are E. coli-based strategies utilizing protein 
fusions to improve yield (7–14). E. coli has several advantages for membrane protein 
overexpression: defined growth media is relatively inexpensive, numerous genetic tools 
are available for straightforward cell and target protein manipulation, and several 
expression conditions are established for large-scale synthesis (10,15). In particular, 
fusions that direct hydrophobic polypeptides into inclusion bodies have been 
particularly successful for cell-based membrane protein overexpression by minimizing 
toxicity associated with disruption of bacterial membranes (11,13,14) Both soluble and 
insoluble fusions have also been effective in improving membrane protein yield from 
cell-free expression systems (12). However, in all cases, no single fusion protein was 
identified that gave consistently high expression independent of the particular target 
membrane protein. Furthermore, the effectiveness of many fusion protein vectors is 
limited to expressing fragments of, rather than full-length membrane proteins. Thus, a 
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range of vectors is typically screened initially in order to identify specific fusions that 
maximize membrane protein production for a new target. 
 To address these issues, we developed a T7-based expression vector (pOmpF) 
using an engineered fragment of outer membrane protein F (OmpF) as a fusion protein 
to direct full-length membrane protein overexpression in E. coli. OmpF is the major 
outer membrane porin in E. coli, and exhibits high stability due to its b-barrel structure, 
including eight short periplasmic β-hairpins and eight extracellular antiparallel β-
strands (16,17). Highyield expression, purification, and refolding protocols have been 
established for OmpF, suggesting it may be an effective fusion partner to promote high-
yield expression of full-length integral membrane proteins (18–20). OmpF as well as 
other b-barrel membrane proteins are also considerably more polar than a-helical 
membrane proteins, and thus the improved solubility of OmpF in aqueous solution 
enhances its refolding using detergents (19–21) We utilized pOmpF to overexpress 
human receptor activity-modifying protein 1 (RAMP1), a type I integral membrane 
protein co-receptor for calcitonin with calcitonin-like receptor (CLR) (22). Prior work 
concerning RAMP1 structure has focused mainly on the extracellular domain, whereas, 
relatively little is known concerning the structure of the transmembrane (TM) and 
cytoplasmic domains (23). We demonstrate that pOmpF is able to generate high-yield 
expression of full-length, human RAMP1, in contrast to other fusion proteins 
commonly used for membrane protein overexpression, and identified conditions that 
promote the stability and structure of the purified co-receptor. Thus, pOmpF provides a 
useful, complementary tool to enable overexpression and purification of full-length 
integral membrane proteins such as RAMP1 for biophysical studies. 
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4.2 Materials and Methods 
4.2.1 Subcloning and plasmid design 
 
The engineered OmpF sequence (amino acids A23-S164; Uniprot ID P02931) 
was designed to include strands 1–7 and remove the N-terminal signal peptide 
sequence. An optimized nucleotide sequence (Genscript) corresponding to the 
polyhistidine tag, fusion protein sequence, polyglycine linker, thrombin cleavage site, 
and MCS were subcloned into the kanamycin-resistant pET-28a(+) vector as a 
NcoI/XhoI fragment to construct plasmid pOmpF (Supplemental Materials Fig. 4.S1). 
Plasmid pTrpLE containing an optimized TrpLE fragment was kindly provided by Dr. 
Jebrell Glover (Department of Chemistry, Lehigh University) (13). Plasmid pBCL99 
was generated by amplifying the corresponding 99-amino acid BclXL fragment 
described previously for high-level membrane protein expression from plasmid pEF6-
BclXL using specific primers, and subcloned as an NcoI-XhoI fragment into plasmid 
pET28a(+) (14,24). The human RAMP1 CDS (amino acids M1-V148; Uniprot ID 
O60894) was generated using overlap extension PCR with synthetic, E. coli codon-
optimized oligonucleotides. The gene was inserted as a BamHI/XhoI fragment in 
pOmpF. 
 
4.2.2 Protein expression 
Auto-induction 
 
The pOmpF-RAMP1 plasmid was transformed into BL21 cells and allowed to 
grow for 1 h in SOC media before 10 µl of cells were plated on a LB agar plate 
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containing kanamycin (50 µg/ml) and grown overnight at 37°C. The following day, 
individual colonies were isolated and grown in selective LB media (50 µg/ml 
kanamycin) overnight at 37°C. The next day, saturated cell culture was diluted 100-fold 
into fresh, selective ZYP media and grown at 37°C for 24 h (25). Cell pellets from 
induced cultures was harvested by centrifugation and stored at –20°C until further use. 
IPTG induction 
 
The pOmpF-RAMP1 plasmid was transformed into BL21 cells and grown for 1 
h in SOC media. 10  µl of transformed cells were then plated on a kanamycin selective 
(50 µg/ml) LB agar plate and grown overnight at 37°C. Colonies were then isolated and 
allowed to grow in selective LB media (50 µg/ml kanamycin) overnight at 37°C. The 
next day, saturated cell culture was centrifuged, spent media decanted, and the cell 
pellet resuspended in fresh M9 minimal media. The cell suspension was then diluted to 
OD600 of 0.4 in fresh M9 minimal media containing 0.5% v/v glucose and 50 µg/ml 
kanamycin, and grown at 20°C for 16 h to equilibrate growth temperature. Equilibrated 
cells were harvested by centrifugation, spent media decanted, then resuspended in fresh 
M9 minimal media. Equilibrated cultures were then diluted to OD600 of 0.4 in M9 
minimal media containing 0.5% v/v glycerol and 50 µg/ml kanamycin, grown at 20°C 
for an hour, then 1 mM IPTG added to induce protein expression. After 16–24 h, cells 
were collected from induced cultures by centrifugation and stored at –20°C until further 
use. 
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4.2.3 Protein purification 
 
Surfactant extraction and solubility test 
 
Induced cultures were centrifuged (12,000 x g) to remove spent media, the pellet 
resuspended in a 1% (w/v) test surfactant solution, then mixed for 20 min. Samples 
were then centrifuged and the supernatant analyzed by PAGE gel electrophoresis 
using 12% acrylamide gels with 1x MES running buffer. To measure the percentage 
recovery of RAMP1 from the whole-cell extract (% soluble), the intensity of the band 
corresponding to RAMP1 in the whole-cell extract was compared to that of RAMP1 
solubilized using a given test surfactant solution using the densiometry function in 
ImageJ. The total volume for each sample was kept constant, and the result reported as 
the ratio of test detergent band intensity relative to the whole-cell extract. 
Inclusion body preparation 
 
Fifty milliliter of induced culture was centrifuged (12,000 x g) for 15 min and 
the supernatant removed. The resulting pellet was resuspended in 50 mL of deionized 
water and sonicated (15 W) for 20 min to disrupt cell membranes. Next, cultures were 
mixed using a stir plate with agitation (200 rpm) for 20 min to release soluble proteins, 
and then centrifuged (12,000 x g) for 15 min. The wash procedure using deionized 
water was repeated a minimum of three times. After three washes, the resulting pellet 
containing primarily OmpF-RAMP1 was resuspended in 5 mL of FC15 buffer (1% w/v 
FC15, 20 mM Tris, pH 8.3), mixed using a stir plate with agitation (200 rpm) for 20 
min, and centrifuged (12,000 x g) for 15 min. The supernatant, containing primarily 
residual contaminating proteins, was decanted, the pellet collected, and the entire FC15 
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wash procedure repeated at least once. To solubilize OmpF-RAMP1, the FC15-washed 
pellet was then resuspended in an equal volume of FC15 buffer supernatant. 
Immobilized metal ion affinity chromatography (IMAC) 
 
Five-hundred microliter of chelating sepharose Ni-NTA resin (GE Healthcare) 
was charged using 0.2 M NiCl2 and equilibrated with 1 ml of FC15 buffer prior to use. 
An equal volume of FC15-solubilized OmpF-RAMP1 solution and settled Ni-NTA 
resin was mixed in a 2 ml microcentrifuge tube for 20 min on a rotator mixer. The 
sample was centrifuged briefly to sediment the resin, and the supernatant containing 
unbound impurities was removed. The resin was then sequentially washed with 1 bed 
volume of FC15 buffer, 4 bed volumes of FC15 IMAC wash buffer 1 (FC15 buffer. 10 
mM imidazole), 1 bed volume of FC15 IMAC wash buffer 2 (FC15 buffer. 20 mM 
imidazole), 1 bed volume of FC15 IMAC wash buffer 3 (FC15 buffer. 30 mM 
imidazole), and 1 bed volume of FC15 IMAC wash buffer 4 (FC15 buffer. 50 mM 
imidazole) to remove bound impurities. Finally, the target protein was eluted with 1 bed 
volume of FC15 IMAC elution buffer 1 (FC15 buffer. 100 mM imidazole) and 1 bed 
volume of FC15 IMAC elution buffer 2 (FC15 buffer. 300 mMimidazole). 
Thrombin cleavage 
 
One milliliter of IMAC eluate was cleaved with bovine thrombin (BioPharm 
Laboratories) by incubation for 40 min (5 U/ml thrombin, 2.5 mM CaCl2) with mixing 
at room temperature on a rotisserie. 
Cation exchange chromatography (CEC) 
 
Fivehundred microliter of SP Sepharose (GE Healthcare) was equilibrated with 
1 ml of FC15 buffer, then an equal volume of thrombin-cleaved OmpF-RAMP1 
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solution and settled SP Sepharose was mixed for 10 min. The mixture was centrifuged 
briefly to sediment resin and the supernatant containing unbound protein removed. The 
resin was then sequentially washed with 4 bed volumes of FC15 buffer, 1 bed volume 
of FC15 IEX wash buffer 1 (FC15 buffer, 10 mM NaCl), 1 bed volume of FC15 IEX 
wash buffer 2 (FC15 buffer. 20 mM NaCl), 1 bed volume of FC15 IEX wash buffer 3 
(FC15 buffer. 30 mM NaCl), and 1 bed volume of FC15 IEX wash buffer 4 (FC15 
buffer . 50 mM NaCl) to remove any weakly bound material. Solublilized RAMP1 was 
eluted with 1 bed volume of FC15 IEX elution buffer 2 (FC15 buffer. 500 mM NaCl). 
NaCl was removed by dialysis against a 1000-fold excess of low-salt FC15 buffer using 
a 3500 MWCO dialysis membrane (Pierce). 
 
4.2.4 Immunoblotting 
 
Twenty microliter of protein sample was mixed with 5 µl of 5x Lammeli sample 
buffer, heated briefly at 90°C, then loaded onto a 12% acrylamide gel with MES 
running buffer. Samples were run for 1 h at 200 V using Lammeli running buffer, then 
transferred to a nitrocellulose membrane (Amersham Hybond ECL) for 90 min, blocked 
for 1 h at room temperature using 5% milk in TBST, then incubated with a 1000x 
dilution of anti-RAMP1 rabbit polyclonal antibody (ab96125, abcam) for 16 h at 4°C or 
a 3000x dilution of anti-His antibody (Cell Signaling) for 1 h at room temperature. The 
membrane was washed with TBST, exchanging solution every 5 min, followed by 
incubation with a 3000x dilution of goat polyclonal anti-rabbit IgG antibody (ab6721, 
abcam) for 1 h at room temperature or a 15,000x dilution of anti-mouse IgG antibody 
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for 1 h at room temperature. Membranes were developed using a chemiluminescent 
substrate (GE) and imaged using a Typhoon imager. 
 
 
4.2.5 Mass spectrometry 
 
The MW of purified human RAMP1 protein was verified by MALDI-TOF mass 
spectrometry. Protein samples in FC15 buffer were mixed with sinapinic acid matrix 
(acetonitrile/water/TFA: 50/50/0.1) at a 1:1 ratio, spotted on a MSP 96 target ground 
steel plate (Bruker) and allowed to air dry before analysis using a Microflex mass 
spectrometer (Bruker Daltonics). 
 
 
4.2.6 Circular dichroism (CD) 
 
Spectra were collected using 400 µl of dialyzed protein samples (0.14 mg/ml) in 
0.1 cm quartz cuvettes (Starna) using a J-815 CD spectrometer (JASCO) with heated 
sample chamber. The scanning speed was set to 500 nm/min and measurements 
collected from 180 to 260 nm. All CD spectra were collected in nanopure water 
(Millipore) containing 1% w/v FC15; this solution was also used for background 
subtraction. For thermal stability measurements, samples were first heated to a specific 
temperature (in 10° increments) from 20 to 60°C and then cooled down to 20°C. The 
spectrum of buffer containing 1% w/v FC15 at each temperature was used for 
background subtraction. Raw spectra (in mdeg) were converted to molar ellipticity (in 
degree cm2/dmol), and percent secondary structure estimated from the converted spectra 
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using the K2D3 online server (26). 
 
 
4.2.7 Fluorescence measurements 
 
Fluorescence emission spectrums (310–410 nm) were measured at 25°C using a 
Cary Eclipse Spectrophotometer (Agilent Technologies) with an excitation wavelength 
of 295 nm. Buffer conditions were identical to those used for CD measurements. For 
free tryptophan, a concentration of 0.01 mg/ml was used. For the disulfide bond 
reducing experiment, a DTT concentration of 10 mM was used. 
 
 
4.2.8 Dynamic light scattering (DLS) 
 
Measurements were performed using a Brookhaven Instruments spectrometer 
and the intensity–intensity time correlation function was measured by means of a BIO-
9000 AT multichannel digital correlator. The scattering angle 90°, 75°, and 60° were 
used. The CONTIN method was used to analyze the normalized electric field time 
correlation function to determine the particle’s apparent diffusion coefficient (D) (27). 
The mean hydrodynamic radius (Rh) was calculated from the Stokes–Einstein equation: 
Rh = (kbT)/(6πηD) 
where kb is the Boltzmann constant, T the temperature, and η the shear viscosity of the 
solvent. Buffer conditions were identical to those used for CD measurements. 
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4.3 Results  
 
4.3.1 Design of pOmpF expression vector 
 
Expression plasmid pOmpF was constructed using a T7 promoter to drive 
overexpression in E. coli. Details of the plasmid design and construction are provided in 
‘‘Materials and Methods Section 4.2.1’’. The main features of the expression system are 
illustrated in Figure 4.1: N-terminal polyhistidine tag, an engineered OmpF fragment 
(amino acids A23-S164; Uniprot ID P02931), a polyglycine linker, a thrombin cleavage 
site, and multiple cloning sites (MCS). In the engineered OmpF fusion, the signal 
peptide of OmpF was removed to prevent protein trafficking to the outer membrane and 
direct inclusion body formation. 
 
 
 
Figure 4. 1. pOmpF Expression Vector Plasmid Map. Key features of pOmpF 
(kanamycin resistant) are illustrated above, including N-terminal poly-histidine 
purification tag, engineered OmpF fragment, poly-glycine linker with thrombin 
cleavage site and multiple cloning site. Fusion protein expression is driven by a T7 
promoter. The translated protein sequence for the engineered OmpF fusion is also 
included. 
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4.3.2 Expression of RAMP1 protein as an OmpF fusion 
 
We generated an in-frame fusion with our engineered OmpF fragment to full-
length human RAMP1 (amino acids M1-V148; Uniprot ID O60894), and compared 
expression to three other commonly used fusions for membrane protein overexpression: 
trpLE, BclXL, and glutathione-S-transferase [pET-42a (+) expression plasmid] (13,14). 
Fusions were expressed in LB broth using BL21 (DE3) cells for 12–16 h at a growth 
temperature of 20°C as described in ‘‘Materials and Methods Section 4.2.2’’. As 
illustrated in Figure 4.2, RAMP1 expression was only observed as a fusion with 
pOmpF, with a prominent band visible by PAGE at the expected fusion MW (35.1 kDa) 
present in the whole-cell extract and confirmed by western blotting using anti-His 
antibody. Furthermore, high-yield OmpF-RAMP1 expression is observed for several 
different media formulations (Fig. 4.3), including autoinduction (ZYP growth media) at 
20°C and 37°C, LB media with 1 mM IPTG at 20°C, and M9 minimal media with IPTG 
at 20°C (25). Thus, the engineered OmpF fragment is able to facilitate overexpression 
of full-length RAMP1, in contrast to other fusions used previously for membrane 
protein overexpression. Furthermore, OmpF fusions can be expressed in minimal media 
at a scale suitable for metabolic labeling and structure determination as well as in rich 
media to increase protein expression levels for biophysical analysis. We also 
successfully expressed a 2 TM fragment of the cognate co-receptor for RAMP1, CLR, 
using pOmpF (Fig. 4.4) under similar conditions to those described for RAMP1, further 
demonstrating the potential of pOmpF to produce single and multi-pass TM proteins at 
a scale appropriate for biophysical studies. 
 90 
  
 
Figure 4. 2. Comparison of RAMP1 Expression with Different Fusion. Full-length 
RAMP1 CDS was subcloned into three different expression vectors (TrpLE, BCL99, 
and pET42) containing commonly used fusions for membrane protein overexpression, 
as well as pOmpF, which contains an engineered OmpF fragment, and pET28, which 
does not contain a fusion tag. RAMP1 fusions were expressed using IPTG induction 
from BL21 (DE3) cells for 12–16 h at a growth temperature of 20°C. A prominent band 
at the expected size (35.1 kDa) for the OmpF-RAMP1 fusion is observed in whole-cell 
lysates from pOmpF, whereas no prominent bands are observed for any of the other 
constructs. Immunoblotting using an anti-His antibody confirms the band at the 
expected size for OmpF-RAMP1 is specific, whereas no bands are observed for any of 
the other constructs. [TrpLE: pET-TrpLE, OmpF: OmpF, BCL99: pBCL99, pET28: 
pET-28a (+), and pET42: pET-42a (+)] 
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Figure 4. 3. Different Induction Conditions for pOmpF Expression Vector. pOmpF 
containing full-length RAMP1 was transformed into BL21 (DE3) cells and expression 
induced using different growth medias, growth temperatures and inducers. Prominent 
bands at the expected size for OmpF-RAMP1 were observed from whole-cell lysates 
expressed using ZYP media at 37°C, ZYP media at 20°C, LB media. IPTG at 20°C, and 
M9 minimal media . IPTG at 20°C (band between 25kDa and 37kDa). [(-): Uninduced 
culture, 37ZYP: ZYP media at 37°C, 20ZYP: ZYP media at 20°C, 37MOP: MOPS 
media at 37°C, 20MOP: MOPS media at 20°C, 37LB: LB media at 37°C, 20LB: LB 
media at 20°C, 37M9: M9 minimal media at 37°C, and 20M9: M9 minimal media at 
20°C]. 
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Figure 4. 4. Anti-His Western Blot on OmpF Fused Human Calcitonin Gene-related 
Peptide Type 1 Receptor (CLR) Fragment (30kDa). The anti-His western blot 
demonstrates the effectiveness of OmpF expression vector expressing a human 
calcitonin gene-related peptide type 1 receptor protein fragment (SeqRef#: 
NP_005786.1) that includes dual transmembrane domains (L237-R336) ((-): uninduced 
culture and (+): 20°C IPTG induced culture).  
 
 
4.3.3 Purification of RAMP1 protein 
 
The overexpressed OmpF-RAMP1 fusions were retained in the insoluble 
fraction of the cell after lysis using 1% Triton X-100 and sonication (Fig. 4.5 and Fig. 
4.6). An advantage of insoluble membrane protein fusions is the ability to use 
differential extraction with detergents, salts and other solutes to selectively enrich for 
the fusion in the insoluble fraction prior to solubilization (28,29). For OmpF-RAMP1, 
we were able to achieve >90% pure OmpF-RAMP1 fusion protein as assessed by 
PAGE (Fig. 4.4A lane WS2) using a series of washes followed by resolubilizing the 
protein in zwitterionic detergent fos-choline 15 (FC15). Further details of the wash and 
solubilization procedure are provided in ‘‘Materials and Methods Section 4.2.3". 
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Figure 4. 5. Extraction and Solubilization of OmpF-RAMP1 as a Function of Surfactant 
Type. A, Induced cultures were lysed, centrifuged and the insoluble fraction mixed with 
a test detergent solution at 1% (w/v) concentration. After incubation, the soluble 
fraction was collected by centrifugation and analyzed by SDS-PAGE. OmpF-RAMP1 
was highly soluble in FC15, FC14, and FC13 and moderately soluble in FC12 and FC11 
(WC: whole cell lysate, FC15: FOS-CHOLINE-15, FC14: FOS-CHOLINE-14, FC13: 
FOS-CHOLINE-13, FC12: FOS-CHOLINE-12, FC11: FOS-CHOLINE-11, FC10: 
FOS-CHOLINE-10, FC9: FOS-CHOLINE-9, and FC8: FOS-CHOLINE-8). B, OmpF-
RAMP1 was solubilized in different concentration of FC15, and the minimum FC15 
concentration necessary to solubilize OmpF-RAMP1 is 1% w/v. Percent solubilization 
of RAMP1 by a given test detergent is reported in terms of the relative ratio of RAMP1 
present in the whole-cell extract versus that in a given test detergent solution. 
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Figure 4. 6. Comparing Extraction and Solubilization of OmpF-RAMP1 as a Function 
of Surfactant Type. Induced cultures were lysed, centrifuged and the insoluble fraction 
mixed with a test detergent solution at 1% (w/v) concentration. After incubation, the 
soluble fraction was collected by centrifugation and analyzed by SDS-PAGE. OmpF-
RAMP1 was only fully soluble in SDS (-80: ANAPOE-80, -58: ANAPOE-58, C13E8: 
ANAPOE-C13E8, C12E10: ANAPOE-C12E10, C12E9: ANAPOE-C12E9, C12E8: 
ANAPOE-C12E8, C10E7: ANAPOE-C10E7, C10E6: ANAPOE-C10E6, X100: Triton X-
100, SDS: Sodium dodecyl sulfate, P20: Polysorbate-20, OG: N-oxytyl-β-D-glucoside, 
and CHAPS: CHAPS). 
 
 
We tested the ability of a series of non-ionic, ionic, and zwitterionic detergents 
to effectively solubilize OmpF-RAMP1, with the expectation that mild detergents will 
be effective at solubilizing the fusion. Of those tested, OmpF-RAMP1 was highly 
soluble in the denaturing detergent SDS as well as the zwitterionic FC detergents FC13 
(77%), FC14 (100%) and FC15 (73%), and moderately soluble in FC11 and FC12 (Fig. 
4.5); percent solubilization for each sample is reported as the ratio of RAMP1 present in 
the detergent extract relative to the whole-cell lysate. FC detergents have been used 
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successfully for solubilization, chromatographic purification, and biophysical 
characterization of a wide range of integral membrane proteins overexpressed in E. coli, 
including G-protein coupled receptors and OmpF (16,30) For FC15, the minimum 
detergent concentration required to solubilize the fusion protein was determined to be 
1% (w/v) (Fig. 4.5B). Therefore the mild zwitterionic detergent FC15 is a suitable 
choice to solubilize OmpF-RAMP1 directly, without a need for harsh denaturants or 
high detergent concentrations (5,31). 
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Figure 4. 7. Purification of RAM1 from OmpF-RAMP1 Fusion. A, Cellular proteins 
from whole-cell extracts are removed by successive washes of Insoluble fraction using 
water (WW) and FC15 (WS) (WW1: water wash 1, WW2: water wash 2, WW3: water 
wash 3, WW4, water wash 4, WS1: FOS-15 buffer solubilization 1, WS2: FOS-15 
buffer solubilization 2, and WS3: FOS-15 buffer solubilization 3). B, Immobilized 
metal ion affinity chromatography (IMAC) was used to isolate His-tagged OmpF-
RAMP1 fusion protein using a series of low imidazole washes (IMW; 10–30 mM) to 
remove impurities followed by high imidazole wash (IME; 100 mM) to elute bound 
OmpF-RAMP1 (UB: unbound, IMW1: IMAC wash 1, IMW2: IMAC wash 2, IMW3: 
IMAC wash 3, IMW4: IMAC wash 4, IMW5: IMAC wash 5, IME1: IMAC elution 1, 
and IME2: IMAC elution 2). C, Purified protein samples were transferred to a 
nitrocellulose membrane, transferred proteins were visualized using Ponceau S stain 
and RAMP1 identified in visualized bands by immunoblotting with anti-RAMP1 
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antibody (Anti-RAMP1). The anti-RAMP1 immunoblot confirms RAMP1 expression 
in the OmpF-RAMP1 fusion and in the thrombin-cleaved sample to remove OmpF 
(PSUC: Ponceau S stained uncleaved OmpF-RAMP1 fusion, PSC: Ponceau S stained 
thrombin cleaved OmpF-RAMP1 fusion, WBUC: anti-RAMP1 blotted uncleaved 
OmpF-RAMP1 fusion, and WBC: anti-RAMP1 blotted thrombin cleaved OmpF-
RAMP1 fusion). D, Cation exchange chromatography (CEC) at pH 8.3 was used to 
isolate RAMP1 from OmpF and other proteins present in cleavage solution (UC: 
uncleaved, C: cleaved, UB: unbound, EXW1: IEX wash 1, EXW2: IEX wash 2, EXW3: 
IEX wash 3, EXW4: IEX wash 4, EXE1: IEX elution 1, and EXE2: IEX elution 2). E, 
MALDI MS of purified RAMP1 from lane EXE1 in Figure 4D indicates a single peak 
at 17 kDa, which corresponds to MW of RAMP1 (Theoretical pI and MW: OmpF-
RAMP1 [6.59 and 35.1kDa), OmpF (5.73 and 17.4kDa), RAMP1 (8.56 and 17.8kDa), 
Bovine Thrombin (7.05)]. 
 
 
For purification, IMAC affinity chromatography was used as an initial capture 
step for the OmpFRAMP1 fusion protein, followed by ion exchange chromatography to 
separate OmpF from RAMP1 after treatment with thrombin. Having pre-washed the 
OmpF-RAMP1 fusion present in the insoluble fraction to improve purity to >90% (Fig. 
4.7A), the fusion was immobilized onto IMAC, washed with low concentrations of 
imidazole to remove residual impurities and eluted using 100 mM imidazole (Fig. 
4.7B). After IMAC, the OmpF-RAMP1 fusion was essentially pure as assessed by 
PAGE. Thrombin treatment of the eluate was robust to the presence of FC15 and 
imidazole, and >90% of RAMP1 was released from OmpF after a 40-min digestion. 
Importantly, OmpF-RAMP1 and RAMP1 both remained soluble and stable in FC15 
throughout the digest. Due to the similar sizes of RAMP1 (17.8 kDa) and OmpF (17.4 
kDa), an anti-RAMP1 western blot was used to confirm the presence of full-length 
RAMP1 before and after thrombin treatment. As observed on nitrocellulose membranes 
visualized by Ponceau S stain (Fig. 4.7C), two prominent species between 15 and 20 
kDa are present in the thrombin-treated sample. However, only one of the two species 
 98 
present in the thrombin-treated sample were reactive against anti-RAMP1, confirming 
RAMP1 was successfully removed from the OmpF fusion in a soluble, stable form. 
Interestingly, RAMP1 appeared to migrate faster than OmpF on a PAGE gel, which 
may be a result of altered detergent binding to TM helices resistant to unfolding by SDS 
(32). Thus, FC15 is compatible with chromatographic capture of OmpF-RAMP1 using 
IMAC, thrombin cleavage and stabilization of full-length RAMP1 in solution. 
 Cation exchange chromatography (CEC) was used to remove residual OmpF 
and thrombin from FC15-solubilized RAMP1. CEC was preferred based on the 
predicted isoelectric point (pI) of RAMP1 (8.6), which is considerably higher than that 
of OmpF-RAMP1 (6.6), OmpF (5.7) and thrombin (7.0). After loading the thrombin 
digestion mixture onto the CEC at pH 8.3, an initial isocratic wash with low NaCl (50 
mM) at pH 8.3 was used to remove OmpF-RAMP1, OmpF, and thrombin. A 
subsequent isocratic wash at high NaCl concentration (0.5M) then enabled purification 
of bound, FC15-solubilized RAMP1 (Fig. 4.7D). Purity was assessed MALDI MS (Fig. 
4.7E), which indicates a single species at the expected MW for full-length, human 
RAMP1. 
 
4.3.4 Characterization of purified RAMP1 protein from pOmpF expression vector 
 
Using dynamic light scattering (DLS), we observe a single, monodisperse 
population for FC-solubilized, purified RAMP1 with an estimated hydrodynamic radius 
(3 nm) consistent with a RAMP1-FC15 complex (Fig. 4.8). Moreover, in order to 
confirm purified RAMP1 is soluble and stable after purification from OmpF, we used 
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circular dichroism (CD) to measure the secondary structure of purified RAMP1 
solubilized in FC15. At 20°C, the two local minima at 208 nm and 222 nm and 
maximum between 190 and 195 nm indicative of α-helical secondary structure (Fig. 
4.9) (33). We also examined the thermal stability of RAMP1 secondary structure 
between 20 and 60°C in FC15, and observed only a modest (5%) decrease in the molar 
ellipticity at 195 nm and increase in the molar ellipticity at 208 nm at 60°C which was 
reversible upon cooling to 20°C. Importantly, no precipitation of RAMP1 was observed 
over the entire 20–60°C temperature range using either FC15. Thus, we conclude 
RAMP1 is stable in FC15 at the level of secondary structure, and the observed 
secondary structure is insensitive to temperature. We also measured the secondary 
structure and thermal stability of purified RAMP1 in 1:1 dodecyl β-D-maltoside:FC15 
(Fig. 4.10) and found essentially identical results to FC15 alone, indicating the 
secondary structure and thermal stability of purified RAMP1 is independent of 
detergent type.  
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Figure 4 8. Dynamic Light Scattering Analysis of RAMP1-FC15 Complex. A 
homogeneous population of RAMP1 solubilized in FC15 is observed, with an estimated 
hydrodynamic radius of about 3 nm, which is consistent with a RAMP1 monomer 
solubilized in FC15. 
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Figure 4. 9. Circular Dichroism Spectra of Purified RAMP1. All spectra represent an 
average of three scans. As temperature was increased to 60°C, the minima at 208 nm 
and 222 nm increased slightly (5%), but the overall spectra remained α-helical. The 
change in minima was completely reversible upon cooling samples to 20°C. (D: 
reducing temperature). 
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Figure 4. 10. Circular Dichroism Spectra of Purified RAMP1. All spectra represent an 
average of three scans. A, Circular dichroism spectra of RAMP1 at 20°C showed that 
RAMP1 is primarily α-helical (local minima at 208 and 222nm) in both detergent 
conditions (1% FC15 and 1% FC15 + 1% DDM). B, CD spectra of RAMP1 solubilized 
in 1% FC15 + 1% DDM detergent mixture is essentially identical to that measure for 
1% FC15, indicating α-helical secondary structure, and remained constant over a wide 
range of temperatures (20-60°C). 
 
As further confirmation that the FC15-RAMP1 complex forms a stable tertiary 
structure, we compared tryptophan emissions spectra for wild-type RAMP1 with and 
without reducing agent dithiothreitol (DTT). Compared to free tryptophan, which has an 
emissions maximum at 359 nm, wild-type RAMP1 is significantly blue-shifted, with an 
emissions maximum at 340 nm (Fig. 4.11), consistent with burial of extracellular 
tryptophan residues. Addition of DTT to wild-type RAMP1 causes a nearly 25% 
increase in the intensity of the tryptophan emission spectrum within 10 min; the 
increase in fluorescence under reducing conditions is indicative of tryptophan 
fluorescence quenching in the non-reduced, purified RAMP1-FC15 sample due to 
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disulfide bond formation (34). 
 
Figure 4. 11. Fluorescence Spectrum of Wild-type and Reduced RAMP1. An excitation 
wavelength of 295 nm was used to selectively observe the effect of tryptophan residues. 
Compared to the fully solvent exposed tryptophan sample (maximum at 359 nm), the 
fluorescence spectrum of unreduced RAMP1 is blue shifted (maximum at 341 nm), 
indicating burial of the extracellular tryptophan residues. Furthermore, the 25% increase 
in spectrum maximum in the reduced RAMP1 sample relative to unreduced RAMP1 is 
consistent with the presence of disulfide bonds, which when reduced, lead to increased 
tryptophan exposure (No DTT: no DTT added, 2min DTT+: 2 min after DTT was 
added, 3min DTT+: 3 min after DTT was added, 10min DTT+: 10 min after DTT was 
added, and Tryptophan: free tryptophan). 
 
4.3 Discussion  
 
A major challenge in working with membrane proteins is identifying conditions 
that promote both solubility and stability of the fusion and purified target membrane 
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protein. In general, membrane proteins are only soluble in strong denaturants such as 
urea and SDS or organic solvents such as formic acid due to their hydrophobicity. 
However, harsh conditions typically used for solubilization, such as 70% formic acid, 
1–5% SDS or 8M urea, not only unfold the membrane protein, but may also lead to 
irreversible denaturation and aggregation (28,35). Thus, choice of a polar fusion 
protein, such as OmpF, can often enhance the overall solubility of the fusion, thereby 
reducing the amount of denaturant required or in some cases, enable solubilization 
using non-denaturing detergents. 
When designing the pOmpF Expression Vector, we found that the truncated 
15.4 kDa fragment (A23-S164) of OmpF including strand 7 (G157-S163) was most 
robust to consistent, high-yield expression, and was therefore chosen for further study. 
We also included several features in the pOmpF Expression Vector to facilitate the 
purification process of the target protein: the addition of an N-terminal poly-histidine 
tag in-frame with the expressed protein enables purification via IMAC and 
immunoblotting to confirm expression from cell lysate and the incorporation of a 
thrombin cleavage site allows the option of cleaving the target protein from aqueous 
solutions in a detergent-solubilized, native-like state. Previous work has indicated that 
thrombin is a suitable protease for cleavage of membrane protein fusions, and is largely 
insensitive to the type of detergent present when solubilizing fusion proteins (36).  
To confirm the protein produced by pOmpF Expression Vector has the native 
structure is extremely critical for further protein structural determination purpose. With 
that in mind, we need to prove that our purified RAMP1 protein constitutes the native 
RAMP1 structure and this is achieved through several experimental techniques 
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including DLS, CD, and Tryptophan fluorescent quenching. First, DLS results showed 
that purified RAMP1 protein is in a monodisperse form with an estimated 
hydrodynamic radius of 3nm, indicating the peptides were not in large aggregates. 
Then, we used K2D3 to extract secondary structure from the experimental CD spectra 
of purified RAMP1 (26) and found full-length RAMP1 is composed of 90% α-helix, 
with negligible β-strand. For comparison, the previously published RAMP1 
extracellular domain crystal structure (PDB 2YX8) is comprised of a three-helix bundle 
with approximately 81% α-helix, which is less than the estimated 90% helical content 
by CD for full-length RAMP1 (23). Thus, we conclude the RAMP1 TM and likely 
cytosolic domains are also contributing to the additional α-helical secondary structure 
estimated by CD for full-length, TM RAMP1. Given that RAMP1 is a type I integral 
membrane protein with a predicted single, TM α-helix, the experimentally measured 
increase in helicity for full-length, TM RAMP1 versus soluble, extracellular RAMP1 is 
not surprising. Thus, we conclude that FC15 is an appropriate detergent for stabilization 
of purified, full-length RAMP1, with the measured secondary structure (90% α-helix) 
consistent with the expected result based on the previous crystal structure for the 
RAMP1 extracellular domain (23). 
 Additionally, we compared tryptophan emissions spectra for wild-type RAMP1 
with and without reducing agent dithiothreitol (DTT) to confirm that the FC15-RAMP1 
complex forms a stable tertiary structure. RAMP1 is predicted to have three 
extracellular disulfide bonds that contribute to tertiary structure, and multiple studies of 
the effects of disulfide bond formation on protein tertiary structure have demonstrated 
that an increase in the intensity of tryptophan fluorescence upon disulfide bond 
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reduction occurs concomitant with an increase in the partial molar volume due to loss of 
tertiary structure (34,37). RAMP1 has also been shown to regulate the glycosylation of 
its cognate co-receptor CLR, which could potentially influence the tertiary structure of 
RAMP1 in a CLR-RAMP1 heterodimeric complex (38). However, previous studies of 
E. coli expressed CLR-RAMP1 extracellular domain fusions have demonstrated 
comparable ligand binding affinity to full-length receptors in mammalian membranes 
despite not being glycosylated (39). Thus, we conclude that RAMP1 assumes a tertiary 
structure consistent with a stable, folded state, particularly when considered along with 
the expected secondary structure (Figs. 4.9 and 4.10), monodispersity (Fig. 4.8), and 
thermal stability (Figs. 4.9 and 4.10) measured for RAMP1-FC15. 
Moreover, pOmpF Expression Vector has really high membrane protein 
expression efficiency. We found that from an initial culture volume of 25 mL, we are 
able to purify approximately 1 mg of RAMP1 solubilized in FC15. Thus, using RAMP1 
as a representative integral membrane protein, we anticipate yields of purified, target 
membrane protein on the order of 1–10 mg purified receptor per liter culture from 
pOmpF, which enables membrane protein purification on a scale necessary for 
biophysical and structural studies.  
 
4.5 Conclusion 
 
The engineered OmpF fusion (pOmpF) provides a novel, complementary vector 
to others used for high-yield expression and purification of full-length, integral 
membrane proteins from E. coli. In particular, we find that the engineered OmpF 
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truncation enables overexpression of full-length integral membrane proteins such as the 
17 kDa human RAMP1 in a form suitable for isolation and enrichment from whole-cell 
lysates, yet provides adequate solubility to enable extraction directly into zwitterionic 
detergents such as FC15 without a need for harsh denaturants. High-yield expression of 
human RAMP1 using pOmpF is observed from a variety of expression conditions, 
including minimal media suitable for metabolic labeling and enriched autoinduction 
broth for high-density protein expression. The ability to extract soluble, stable 
membrane protein fusion directly from cell lysates into FC15 simplifies subsequent 
purification, with a single IMAC capture step capable of purifying the fusion to near 
homogeneity. Furthermore, the solubility and stability of the FC15-solubilised OmpF-
RAMP1 fusion enables removal of the OmpF fusion and recovery of the purified, full-
length target membrane protein in yields sufficient for biophysical and structural 
characterization. In the case of purified, full-length RAMP1, the experimentally 
measured secondary structure by CD was consistent with the previous structure of full-
length human RAMP1 extracellular domain, exhibited high thermal stability and 
tryptophan fluorescence emissions spectra consistent with a folded, stable RAMP1 
tertiary structure (23). Overall, the engineered OmpF provides a useful method for 
robust, high-yield membrane protein expression and purification, particularly in 
instances where other commonly-used fusions tags are not effective at improving 
expression yield or conferring solubility. 
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Chapter 5 
THE ASSOCIATION BETWEEN CALCITONIN RECEPTOR-LIKE 
RECEPTOR (CLR) AND RECEPTOR ACTIVITY MODIFYING 
PROTEIN 1 (RAMP1) TRANSMEMBRANE DOMAINS IS 
CRITICAL FOR FORMING A FULLY FUNCTIONAL 
CALCITONIN GENE-RELATED PEPTIDE RECEPTOR 
 
 
Calciton receptor-like receptor (CLR), a class B G-protein coupled receptor 
(GPCR), when bound with receptor activity modifying protein 1 (RAMP1), forms a 
specific calcitonin gene-related peptide (CGRP) receptor. Many complications had 
been associated with this co-receptor complex and obtaining detail understanding on 
how CLR and RAMP1 associate is critical for superior antagonist design. In this study, 
we identified a highly conserved RAMP1 TM P-x-x-x-T motif through genetic sequence 
alignments. By applying site-directed mutagenesis to substitute the motif residues and 
various biochemical experimental techniques, we were able to demonstrate the 
importance of this motif in CLR-RAMP1 association and signaling. Furthermore, our 
DN-AraTM results on individual CLR and RAMP1 transmembrane (TM) domains 
suggested CLR TM3, TM6, and TM7 might play a significant role in associating with 
RAMP1.   
 
 
5.1 Introduction 
Calcitonin receptor-like receptor (CLR) is a class B G-protein coupled receptor 
(GPCR), a family of proteins which pass through the plasma membrane seven times and 
represent the primary receptor-type targets for prescription drugs. CLR is associated 
with numerous disease conditions such as osteoporosis, diabetes, obesity, venous 
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insufficiency, and various cardiovascular disorders (1). The ligand-specificity of CLR is 
dependent on its interaction with other accessory membrane proteins (2, 3). CLR alone 
does not recognize any ligand. Ligand binding occurs only after association with a 
group of co-receptors called receptor activity modifying proteins (RAMPs) (4). There 
are three types of RAMPs (RAMP1, RAMP2 and RAMP3), which share less than 30% 
sequence identity (4). The RAMPs are 148-175 amino acids in size with a cleavable N-
terminal signaling peptide and similar topology: a large N-terminal extracellular domain 
(~100 aa), one transmembrane spanning domain (~20 aa) and a short C-terminal 
intracellular domain (~10 aa) (5). When associating with RAMP1 in a 1:1 ratio, CLR 
forms a specific receptor for calcitonin gene-related peptide (CGRP), which is one of 
the most potent vasodilators discovered thus far (6). Increased cranial circulation of 
CGRP has been associated with migraines and antagonism of CGRP receptors has 
become an important target for migraine treatment (7). Nevertheless, current 
antimigraine treatments such as sumatriptan cause vasoconstriction and other CLR 
antagonist chemical-based drugs either exhibit poor oral bioavailability (BIBN 4096 
BS) or cause liver damage (MK-0974) (7, 8). In order to design more effective migraine 
medications, it is critical to understand how CLR and RAMP1 interact and how this 
receptor mediates signal transduction.  
While there is substantial information regarding the domains of RAMP1 which 
are critical for ligand binding, little is known about how it associates with CLR and 
forms a functional CGRP receptor (9). Previous studies have shown that the RAMP1 
extracellular domain alone is sufficient for N-glycosylation, trafficking, and signaling of 
CLR; however, the half minimum effective concentration (EC50) of CGRP ligand was 
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increased ~4000 fold compared to the full-length RAMP1 receptor (10). Other studies 
have shown that the CLR-RAMP1 oligomer is no longer observed on the membrane 
surface when RAMP1 transmembrane (TM) domain was deleted, whereas there is no 
effect in signaling when the short RAMP1 intracellular domain is deleted (11). All 
evidence points toward the direct functional significance of the RAMP1 TM domain in 
orienting RAMP1 to form the CLR-RAMP1 complex in a ligand specific manner.  
In the current study, we identified a highly conserved P-x-x-x-T motif within 
RAMPs TM domain. Through BRET analysis, a cylic AMP (cAMP) functional assay, 
TM peptide circular dichroism analysis, and zebrafish gene knockdown and rescue 
experiments, we were able to demonstrate the significant role this motif plays in CLR-
RAMP1 association and signaling. We also examined individual CLR TM and RAMP1 
TM domain interaction using DN-AraTM assay and identified CLR TM4, TM6 and 
TM7 as potential RAMP1 TM association partners.  
 
5.2 Materials and Methods 
5.2.1 Subcloning 
 
Unless otherwise stated, standard molecular biology techniques were used. All 
constructs used were verified by DNA sequencing (Genewiz).  
 For BRET assay, full-length human RAMP1 receptor sequence was amplified 
from plasmid (OriGene) and cloned into pGFP2-N2 as an NheI/KpnI fragment. Full-
length human CLR receptor sequence was amplified from plasmid (OriGene) and 
cloned into pRluc-N2 as an XhoI/KpnI fragment. RAMP1 mutants T126A, T128I, 
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T130I, and T134I were generated by site-directed mutagenesis using QuikChange II 
Site-Directed Mutagenesis Kit (Agilent Technologies).  
 For cAMP functional assay, full-length RAMP1 receptor sequence was 
amplified including a stop codon at the end from plasmid (OriGene) and cloned into 
pGFP2-N2 as an NheI/KpnI fragment. 
 For DN-AraTM assay, RAMP1 TM sequence (I106-V138) was amplified from 
plasmid (OriGene) and cloned into pAraTMwt as a SacI/KpnI fragment. A flexible 
poly-proline linker sequence (RQLPTAAPEPAKV) was inserted between RAMP1 and 
AraC protein to allow proper functioning of the DN-AraTM assay. Individual CLR TM 
sequence (TM1: Y143-S170, TM2: S170-A197, TM3: V210-L240, TM4: Q250-Y277, 
TM5: S286-I317, TM6: K333-G358, and TM7: E363-Q392) was amplified from 
plasmid (OriGene) and cloned into pAraTMDN as an SacI/KpnI fragment. A flexible 
poly-proline linker sequence (RQLPTAAPEPAKV) was inserted between CLR TM 
domains and AraC* protein (transcription inactivated form of AraC protein) to allow 
proper functioning of the DN-AraTM assay. 
 
5.2.2 RAMP TM sequence alignment 
 
RAMP TM sequences were obtained from Protein Data Bank (PDB) and the 
highly conserved amino acids were identified by Weblogo tool. The statistical 
significance of the identified conserved motif was analyzed using TMSTAT. 
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5.2.3 Bioluminescent resonance energy transfer (BRET) assay 
 
8 µg of RAMP1 or mutant RAMP1-GFP and CLR-Rluc fusions were 
transfected into HEK293 cells by electroporation (GenePulser, Bio-Rad) using the 
HEK293 preset protocol in HEBS buffer (pH 7.05). Immediately after electroporation, 
cells were transferred to a white, round-bottom 96 well plate (100 µL of cells per well) 
in DMEM containing 10% FBS with L-glutamine/VitaMax supplements and 1% 
Penn/Strep, and incubated at 37°C and 5% CO2 for 48 h. Media was removed, cells 
were washed once with 100µL of PBS per well before 100µL of BRET buffer (0.1 g/L 
CaCl2, 0.1 g/L MgCl2, and 1 g/L D-glucose in PBS) was added to each well. 5µL of 
Deep Blue C (GoldBio) was added to each sample well, and luminescence 
measurements (Filter 1: Green and Filter 2: Magenta) were collected using a M200 
Infinity plate reader (Tecan) over the course of 10 seconds. The energy transfer 
efficiency is calculated by dividing the intensity of the signal for the green channel by 
the intensity of the signal for the magenta channel (12): 
 
Energy Transfer Efficiency = (GFP Signal at 515nm) / (Magenta Signal at 410nm) 
 
The expression level of each eGFP2-fused and Rluc-fused RAMP1 and CLR proteins 
was evaluated through western blotting against anti-GFP and anti-Rluc antibody 
respectively. Loading control was evaluated through western blotting against anti-
tubulin antibody and HEK293 cells expressing empty eGFP2 and Rluc vectors were 
used as negative control for BRET.  
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5.2.4 Cyclic adenosine monophosphate (cAMP) functional assay 
 
8 µg of RAMP1 or mutant RAMP1 and pGloSensorTM -20F cAMP Plasmid 
(Promega) were transfected into HEK293 cells by electroporation (GenePulser, Bio-
Rad) using the HEK293 preset protocol in HEBS buffer (pH 7.05). Immediately after 
electroporation, cells were transferred to a white, round-bottom 96 well plate (100 µL of 
cells per well) in DMEM containing 10% FBS with L-glutamine/VitaMax supplements 
and 1% Penn/Strep, and incubated at 37°C and 5% CO2 for 24 h. LAR II (firefly 
luciferase substrate) and Stop & Glo Reagent (rennila luciferase substrate) were 
prepared as described by Dual-Luciferase Reporter Assay System protocol (Promega). 
A final concentration of 10-5 M αCGRP was added to the cells and allows the cells to 
incubate for 1h. After 1h, the media was removed. 50µL of LAR II was added to each 
well and luminescence measurements were collected using a M200 Infinity plate reader 
(Tecan) over the course of 20 minutes. Following that, 50µL of Stop & Glo Reagent 
was added to each well and measurements were collected until maximum luminescence 
is observed. The cAMP signal was calculated by dividing the maximum LAR II 
luminescent signal by maximum Stop & Glo Reagent luminescent signal. 
 
5.2.5 Circular dichroism analysis of RAMP1 TM peptides 
 
RAMP1 TM wt (KGSILYPFIVVPITVTLLVTALVVWK), RAMP1 TM T128I, 
and RAMP1 TM T130I peptides were chemically synthesized by GenScript. The 
peptides were solubilized in 1% w/v fos-choline 15 detergent using a bath sonicator. 
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Spectra were collected using 200 µL of peptide samples (~1 mg/mL) in 0.1 cm quartz 
cuvettes (Starna) using a J-815 circular dichroism spectrometer (JASCO). The scanning 
speed was set to 500 nm/min and measurements collected from 180-260 nm. The 
spectrum for buffer containing 1% w/v fos-choline 15 was used for background 
subtraction (13). Raw spectra (mdeg) were converted to molar ellipticity (degree cm2 
dmol-1) 
 
5.2.6 Zebrafish RAMP1 gene knockdown and rescue 
 
For RAMP1 gene knockdown, zebrafish embryos were injected with 10 ng of 
each complementary RAMP1 MO (UTR1 and UTR2), both of which target the 5’ UTR 
region of RAMP1. As controls, we used 2 MOs (scr) with scrambled sequences. For 
RAMP1 phenotype rescue, zebrafish embryos were injected with RAMP1-MOs 
followed by RAMP1 mRNA synthesized from plasmid pCS2 to rescue RAMP1 
expression. Full-length zebrafish RAMP1 coding sequence was amplified from 
zebrafish cDNA using specific primers and subcloned into plasmid pCS2 as an 
EcoRI/XhoI fragment. Using site-directed mutagenesis, we also generated point 
mutations P126A and T130I in RAMP1-pCS2. 
5.2.7 DN-AraTM assay 
 
Plasmids pAraTMDN, pAraTMwt, and pAraGFPCDF were co-transformed into 
the AraC- deficient E. coli strain SB1676 (The E. coli Genetic Stock Center at Yale 
University) and streaked on selective LB plates (100 µg/mL ampicillin, 50 µg/mL 
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kanamycin, and 100 µg/mL spectinomycin). 1 colony was picked from each construct 
and grown in 4 mL selective LB media for 16 h at 37°C and 200rpm. After 16 h, the 
cultures were diluted to A600 of 0.5 in three wells on a 2.0 mL 96 deep well PP plate 
(PlateOne) with each well containing 400 µL of selective LB media (100 µg/mL 
ampicillin, 50 µg/mL kanamycin, 100 µg/mL spectinomycin, and 1 mM IPTG) and 
grown for an additional 16 h at 37°C and 300 rpm. 200 µL of cultures from each sample 
was transferred to a black 96-well, clear bottom plate (Greiner) and a series of 2-fold 
dilutions was prepared using selective LB media. A600 measurements and GFP 
fluorescence emissions spectra (excitation maximum at 485nm and emissions maximum 
at 530nm) were collected using a M200 Infinity plate reader (Tecan). Results are 
reported as the ratio of fluorescence emission at 530 nm to absorbance at 560 nm and 
normalized to the negative control (pAraGFPCDF transformed cells) (14). 
 
5.3 Results 
5.3.1 Identification of a conserved RAMP1 TM motif through sequence alignments 
 
Through a cross-species TM sequence analysis (Figure 5.1), we were able to 
identify a highly conserved TM domain P-x-x-x-T motif. TMSTAT, an online program 
developed by Engelman lab which compares a provided TM sequence to a membrane 
protein database in order to determine the statistical significance and frequency of the 
given TM sequence, found that the P-x-x-x-T motif was over-represented in known TM 
helices (Odds ratio=1.07), indicating that this motif may play a significant role in TM 
receptor function (15).  
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Figure 5. 1. RAMP TM domain sequence alignments. The P-x-x-x-T motif is highly 
conserved among human RAMPs and across species, with the registry of the motif 
within the transmembrane region varying among RAMP family members. 
 
 
5.3.2 Examination of the conserved RAMP1 TM motif in CLR-RAMP1 association 
through BRET assay 
BRET is an in vivo mammalian cell-based method used to study receptor 
dimerization. We applied BRET as a mean to observe how mutations within this 
conserved P-x-x-x-T motif affect CLR-RAMP1 heterodimerization. In the case of 
studying CLR-RAMP1, the CLR receptor is fused to RLuc and the RAMP1 or mutant 
RAMP1 (single amino acid substitution within the conserved P-x-x-x-T motif) receptor 
is fused to GFP2. Conservative amino acid mutations were made such that the size 
variation between the native and the substituted side-chains was minimized, for 
example proline was mutated to alanine and threonine to isoleucine.   
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Figure 5. 2. RAMP1 T130I mutant disrupts CLR-RAMP1 association in HEK cells as 
shown by BRET. All RAMP1 mutations includin P126A, T128I, and T134I had similar 
BRET energy transfer efficiency as the RAMP1 wt. However, a ~50% reduction in 
energy transfer efficiency was observed in RAMP1 T130I mutant.  Experiments were 
repeated three times in triplicate, and error bars represent standard deviation (wt: 
RAMP1 wt, P126A: RAMP1 P126A, T128I: RAMP1 T128I, T130I: RAMP1 T130I, 
and T134I: RAMP1 T134I). 
 
By analyzing the resulting BRET energy transfer efficiency with different RAMP1 
mutants (Figure 5.2), we found that only the T130I mutation (~50% reduction) but not 
the control mutants (T128I and T134I) showed a significant decrease in the energy 
transfer ratio indicative of the disruption of this mutation to CLR-RAMP1 association 
which agrees well with our prediction. Interesting enough, the P126A had no affect on 
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energy transfer ratio. However, BRET only indicates how close the two receptors are, it 
does not provide any information on whether the receptor is functional.  
 
5.3.3 Examination of the conserved RAMP1 TM motif in CLR-RAMP1 signaling 
through cAMP functional assay 
cAMP is a second messenger used by CLR-RAMP1 for intracellular signal 
transduction (10). Studies by Mishima’s group discovered increased levels of cAMP in 
patients under migraine attack (16). Therefore, variation of cAMP levels in the cell 
could be used as an indication of in vivo CLR-RAMP1 activity and possibly migraine 
states. To determine the functional significant of the P-x-x-x-T motif in CLR-RAMP1 
signaling, we transiently expressed RAMP1 or mutant RAMP1 in HEK293 cells, and as 
well as a plasmid that produces a firefly luciferase fusion protein (FLuc). Binding of 
this FLuc with cAMP results in an increase in luminescence and by adding a FLuc 
substrate and inducing with CGRP, the cAMP signal being transduced by the functional 
receptor formed by RAMP1 or mutant RAMP1 with endogenously expressed CLR can 
be monitored in the system. As shown in Figure 5.3, before induced by CGRP, all the 
samples have similar basal cAMP level. After addition of 10-5 M CGRP agonist, we 
observed a significant increase (~1.8 fold increase as compared to the non-ligand 
induced state) in cAMP response for RAMP1 wt, P126A, and T128I samples, but a 
similar cAMP response profile as the negative control (~1.3 fold increase as compared 
to the non-ligand induced state) for RAMP1 T130I sample was observed. The reduction 
in RAMP1 T130I cAMP response is consistent with our prediction of the significance 
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of this threonine within the conserved RAMPs TM motif; however, we see no 
significant penalty in signaling by mutating the RAMP1 P126 residue.  
 
 
Figure 5. 3. RAMP1 T130I exhibits a significant disruption in receptor signaling when 
induced with peptide agonist αCGRP. Experiments were repeated three times in 
quadruplicate, and error bars represent stand error of the mean (wt: RAMP1 wt, P126A: 
RAMP1 P126A, T128I: RAMP1 T128I, T130I: RAMP1 T130I, and +: induced with 10-
5 αCGRP). 
 
 
5.3.4 Zebrafish RAMP1 gene knockdown and rescue 
The expression of RAMP1 receptor in zebrafish was repressed during embryo 
development using the anti-sense morpholinos (MOs) where the morpholino oligos 
bound to the 5’-untranslated region of RAMP1 messenger RNA and interfered 
ribosomal initiation complex from progressing through the 5’ cap to the start codon.  As 
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shown in Figure 5.4, 24 hours post fertilization (hpf), we observed numerous 
cardiovascular defects in zebrafish embryos injected with specific MOs to knockdown 
RAMP1 expression compared to the scrambled randomized MOs (scr) injected 
zebrafish embryos. These defects include cardiac edema, blood pooling through the 
heart chamber, and lack of heart chamber formation. Moreover, the tubule is still able to 
function by pumping blood through the vasculature, but at a significantly reduced rate. 
By 48 hpf, the larvae have severe malformations and gross morphological defects, and 
do not remain viable beyond 48-72 hpf. Our next step was to rescue the phenotype by 
introducing RAMP1 mRNA into the embryos. As shown in Figure 5.5, when we 
introduced the wt RAMP1 mRNA to the RAMP1-MO knockdown zebrafish embryo, 
the zebrafish was able to have fully developed healthy cardiovascular system similar to 
the zebrafish embryos injected with scr MOs. In contrast, when TM mutant RAMP1 
mRNAs (P126A, T130I) were introduced to the embryos, neither of them was able to 
rescue the RAMP1-MO phenotype. Both RAMP1 mutants resulted in enlarged and 
unhealthy cardiovascular system zebrafish phenotype (Figure 5.5).  
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Figure 5. 4. Cardiovascular defects observed in RAMP1-MO treated zebrafish at 24 hpf.  
Embryos were injected with 2 complementary MOs targeting the 5’ UTR  (untranslated 
region) of RAMP1 and compared to controls using scrambled MO sequences (scr). 
Larvae exhibited numerous cardiovascular defects at 24 hpf, including cardiac edema, 
blood pooling throughout the heart chamber and lack of heart chamber formation. 
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Figure 5. 5. Rescue of cardiovascular defects observed in RAMP1-MO larvae with 
wild-type RAMP1 mRNA: Wild-type RAMP1 and point mutations P126A and T130I 
were generated, injected and imaged at 24 hpf. Both mutations occur in the TM region 
of RAMP1, and are predicted to disrupt CLR-RAMP1 complex formation. Strikingly, 
both mutations are unable to rescue the RAMP1-MO phenotype, in contrast to wt-
RAMP1. 
 
 
5.3.5 Circular dichroism analysis of RAMP1 TM peptides 
To examine the contribution of threonine mutation to overall RAMP1 TM 
secondary structure, we chemically synthesized RAMP1 TM peptides (wt, T128I, and 
T130I) and solubilized the peptides in 1% fos-choline w/v 15 micelles, which was 
previously shown to solubilize full-length RAMP1 protein and retain its native folded 
secondary and tertiary structure (13). The secondary structure of each RAMP1 TM 
peptide in fos-choline 15 micelles was determined via circular dichroism. RAMP1 is a 
type I single-span membrane protein which means its TM domain is expected to have 
an α-helical secondary structure. As shown in Figure 5.6, RAMP1 TM wt resembles a 
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semi-α-helical structure. Whereas, both RAMP1 TM T128I and T130I appear to have 
majorly β-sheet secondary structure with a single minimum at around 218nm (T128I at 
217nm and T130I at 215nm). 
 
Figure 5. 6. Circular dichroism spectrum for RAMP1 TM peptides. Both RAMP1 
threonine mutant peptides had a more defined β-sheet secondary structure than the 
RAMP1 wt peptide (wt: RAMP1 wt, T128I: RAMP1 T128I, and T130I: RAMP1 
T130I). 
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5.3.6 DN-AraTM assay analysis on CLR-RAMP1 interacting TM domains 
DN-AraTM assay is an E. coli transcription factor AraC based dominant-
negative system that looks at isolated protein domain interaction and correlates amount 
of heterodimer being formed to observed GFP signal. Homodimerization of the 
reference protein domain gives rise to baseline GFP protein. When the competitor 
protein domain interacts with the reference protein domain, this results in a decrease in 
GFP signal as a consequence of reduction in homodimerization of the reference protein 
domain. We used RAMP1 TM-CYTO domain as the reference protein and individual 
CLR TM domains (TM1-TM7) as the competitor proteins in this experiment. First, we 
observed a strong baseline GFP when we expressed RAMP1 TM-CYTO domain 
indicative of strong homodimer formation (~2 times GFP signal of the negative 
control). Then we introduced individual CLR TM domain as competitor into the system. 
As shown in Figure 5.7, we observed decrease in GFP signals in all samples. Among 
the CLR TM competitors, TM3, TM6, and TM7 had the most significant GFP signal 
drop, indicative of these CLR domains having a higher tendency to form a heterodimer 
with the RAMP1 TM-CYTO domain.   
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Figure 5. 7. DN-AraTM results for RAMP1 and CLR TM domains. Although all CLR 
TM domains forms heterodimer with RAMP1 TM (reduction in fluorescence compared 
to expressing RAMP1 TM alone), CLR TM3, TM6, and TM7 had the most reduction. 
Experiments were repeated three times in quintuplicate, and error bars represent stand 
error of the mean. 
 
 
5.4 Discussion 
Observing a proline residue in a primarily α-helix TM domain of protein is 
interesting because proline has a ring structure side chain which lacks the backbone 
amine group necessary for creating a hydrogen bond with the backbone carbonyl group 
of a residue one turn (or four residues) later, resulting in an unstable kink in the helix. 
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Hydrogen bonding is the primary force required to stabilize the membrane protein's α-
helical structure, therefore, there must be some kind of force to compensate for the lost 
in structural stability caused by the proline residue. One possibility is the contribution of 
stability from the surrounding residues. Studies had shown that threonine side-chain 
hydroxyl group often forms an additional hydrogen bond to the peptide backbone (17). 
α-helices exhibit a repeated i+4 hydrogen bonding, resulting in every 5th amino acid 
residue residing on the same side of the helix, as such, proline and threonine in the P-x-
x-x-T motif of RAMP1 should be on the same face of the helix. The ability of threonine 
to form an additional hydrogen bond could provide structural stability that compensates 
for the resulting helical instability introduced by the proline residue. As a consequence, 
both proline and threonine residues in the P-x-x-x-T motif reinforce the unique kinked 
structure that could a play significant role in CLR-RAMP1 interaciton. In addition, 
studies by the Fleming group indicate that both proline and threonine have a high 
tendency to face the protein interior with a higher packing value, which is a measure of 
occluded surface area, in TM helices; hence, these residues may contribute to formation 
of a tight interface, which may be critical for CLR-RAMP1 interaction (18). 
The results of BRET analysis of RAMP1 P-x-x-x-T mutations revealed that only 
the T130I mutation, and not P126A, affected CLR-RAMP1 association. This is 
surprising due to the fact that the proline side chain is the cause for the kinked structure. 
If the mutation of threonine resulted in disruption of CLR-RAMP1 association is real, 
we should see consequences in CLR-RAMP1 signaling when we introduce the 
mutations. Therefore, we employed the cAMP functional assay to examine the effect of 
the RAMP1 mutation on signaling. Interesting enough, there was no effect in signaling 
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with the proline substitution, but a significant signaling disruption was observed with 
the threonine substitution, which is consistent with our BRET results. The considerably 
moderate change in magnitude of the cAMP signal may be due to the fact that we were 
using endogenously expressed CLR and receptor component protein in pairing with our 
wt and mutant RAMP1 for cAMP activation experiments. Therefore, the signaling 
response we observed was limited to the amount of endogenous receptors found in 
HEK293 cells. CGPR receptor is widely distributed in mammalian cardiovascular 
system and expression of RAMP1 and CLR were observed during the development of 
rat heart (19, 20). These studies suggested RAMP1 could play a critical role in early 
stage cardiovascular system development in the vertebrates. Therefore, if the function 
of RAMP1 receptor was disrupted, we should observe a defect in cardiovascular 
system. We used zebrafish as an in vivo model system to monitor the role RAMP1 
receptor plays in cardiovascular development due to its transparent and quick 
developing nature as well as its ease to manipulate genetically. Our results showed that 
only the wt RAMP1 but not the TM P-x-x-x-T motif residue mutated RAMP1s (P126A, 
T130I) were able to rescue the cardiovascular defect phenotype in the RAMP1-MO 
knockdown zebrafish. Again, threonine residue within the conserved motif was 
important for proper functioning of RAMP1. In contrary to our BRET and cAMP, the 
proline residue actually plays a role in RAMP1 function in this case. The study done by 
Sexson’s group has shown that human RAMP1 can also interact with other receptors 
such as the most common variant of the human calcitonin receptor (hCTR2) (21). The 
inability to rescue cardiovascular defect we observed by the RAMP1 proline mutation 
mRNA could be a result of interference with the function of other co-receptors rather 
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than the CLR receptor, considering zebrafish embryo development is an incredibly 
complex system.   
Our next step was to investigate whether this threonine residue contributes to 
RAMP1 TM domain structure. We solubilized the synthesized RAMP1 TM peptides in 
1% w/v fos-choline and analyzed their secondary structure using circular dichroism. 
Compared to wt RAMP1 TM peptide, both RAMP1 TM T128I and T130I peptides 
resembled much more β-sheet like structure. Though we could not fully reconstitute the 
α-helical structure of RAMP1 TM wt peptide, it is more α-helical-like compared to the 
mutant peptides which implies the threonine plays a important role in stabilizing the 
secondary structure of the proline kink.  
All evidence indicates that the P-x-x-x-T motif is important in maintaining the 
specific structure necessary for CLR-RAMP1 signaling. However, the proline residue 
substitution had no influence in CLR-RAMP1 signaling. This could be explained by the 
evolution hypothesis of the TM proline kinks in GPCRs which states that because this 
kinked structure is so important for function, the surrounding amino acids acclimate to 
this specific structure such that even without the proline residue, the structure is still 
retained (22). This can also explains why CLR-RAMP1 receptor is very sensitive to 
threonine substitution. 
Various studies have shown that TM domain swapping between human 
RAMP1, RAMP2, and RAMP3 had minimum to moderate effect in ligand binding 
affinity and signaling (9, 23). This suggests the interaction between RAMPs and CLR 
through their TM domains is similar. The highly conserved P-x-x-x-T motif exists in all 
human RAMPs and mutagenesis experiments demonstrated the consequence in CLR-
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RAMP1 signaling when this particular structure is disrupted. Moreover, the two-domain 
binding model of CGRP receptor proposed high-affinity binding of CGRP C-terminal 
with N-terminal regions of CLR and RAMP1 (24). This implies that the shape 
complementation resulting from the proline kink may be the driving force for CLR and 
RAMP1 TM domain association. Therefore, the existence of a common structural 
feature between TM domains of RAMPs that dominates CLR-RAMPs interaction is 
highly possible.  
 
5.5 Conclusion 
Though the current study does not provide a complete picture, it is a start for 
understanding how CLR and RAMP1 assembles and forms a functional CGRP receptor 
through their TM domains. Future work such as cysteine mutagenesis and cross-linking 
between RAMP1 and CLR could be used to map out specific TM interaction domains 
and interfaces. 
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Chapter 6 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 The focus of this thesis is developing novel tools to resolve the missing gap in 
membrane protein research and investigate the structural basis for membrane receptor 
signaling for a class B G-protein coupled receptor (GPCR) system: calcitonin receptor-
like receptor (CLR) and receptor activity modifying protein 1 (RAMP1). Overall, we 
developed novel assays for straightforward cooperative membrane protein domain 
interaction analysis (AraTM and DN-AraTM assays) and large quantity membrane 
protein sample preparation for high-resolution structural studies (pOmpF).  
Furthermore, by applying these novel tools along with classical methods to CLR and 
RAMP1, we gained new insights into how these receptors heterodimerize and form a 
functional receptor for calcitonin gene-related peptide (CGRP). Obtaining a full picture 
on how membrane proteins interact with other proteins, are activated by their ligands, 
and signal through conformational changes is a rapidly developing field due to the 
significant roles they play in various biological processes and as important 
pharmaceutical targets.  Therefore, there are plenty of opportunities and future work 
worth exploring. 
 
 
6.1 Application of Modified AraTM Assay on Influenza A Virus M2 Ion 
Channel Protein (AM2) Inhibitor Development 
In Chapter 2, we designed an E. coli transcription factor-based assay, AraTM 
assay, which expresses a chimera protein (contains a maltose-binding protein (MBP) 
and a truncated AraC protein that is connected by a protein domain of interest) in which 
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when homodimerized leads to activation of araBAD promoter and production of green 
fluorescent protein (GFP). Thus, by quantifying the GFP signal, the AraTM assay 
allows for the investigation of coordinated interplay between different domains of 
membrane receptors in forming the specific interface required for functioning. In 
human, there are a large number of membrane proteins in which their function is 
governed by their homooligomeric states and how tightly the oligomer interfaces are 
packed. One particularly important example is the influenza A virus M2 ion channel 
protein (AM2). AM2 is a viral integral membrane protein that forms a homotetramer 
proton channel that plays an important role during the process of viral infection in  
humans (1). After the virus enters the human host by endocytosis, the AM2 proton 
channel initiates endosomal acidification by pumping H+ ions into the cells. This 
acidification leads to the dissociation of matrix proteins from viral ribo nucleo proteins 
(RNP) which eventually results in viral replication in the host (2).  
Blockage of AM2 proton channel by amantadine had been an effective treatment 
for influenza infection for the past couple decades (3). However, recent years the 
number of naturally occurring amantadine-resistant influenza A (H1N1 and H3N2) have 
increased drastically (4). Thus, it is essential to design new AM2 inhibitors that could 
block these variant influenza A viruses with amantadine-resistant AM2. Functional tests 
of AM2 such as electrophysiological readings using two-electrode voltage-clamp 
apparatus are not suitable for drug screening due to the complicity of the experiment 
(5). An ideal solution for drug screening would be a tool that is simple in 
implementation with a high throughput reporting ability. One possible future direction 
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for the application of AraTM is using the AraTM assay coupled with ratiometric 
pHluorin as a pH reporter to design a superior tool for AM2 inhibitor screening (6).  
In the modified AraTM assay, there are two parts: the basic AraTM assay 
(described in Chapter 2) and the ratiometric pHluorin reporter. The basic AraTM assay 
serve two purposes: one is to investigate the contribution of instability or stability of 
different naturally occurring amantadine-resistant AM2 mutations to the AM2 
homotetramer. The other is to verify the expressed AM2 protein are assembled and 
oligormized in their native states. As shown in Figure 6.1, various literature results on 
AM2 mutant homotetramer stability studies are in excellent agreement with our AM2 
mutant AraC assay results (7). Particularly, both amantadine-resistant M2 mutations, 
L26F and S31N, showed stabilizing effects in homotetramer formation. This illustrates 
the AM2 proteins expressed in our AraTM assay behave as native-like structures. For 
the reporter, we would utilize ratiometric pHluorin as an in vivo approach that monitors 
E. coli intracellular pH which is directly linked to AM2 functions. We take advantage of 
the fact that ratiometric pHluorin has distinctive fluorescent spectrum properties 
dependent on the pH of the environment (Fig. 6.2). By adjusting the extra- and 
intracellular pH gradient that forces proton pumping by AM2, we could create a system 
that mimics the in vivo AM2 functional settings and is ideal for rapid AM2 inhibitor 
screening (6). 
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Figure 6. 1. The consequences of AM2 mutations in tetramer dissociation are similar 
between previous published data and our AraTM AM2 data. A, The change in free 
energy of tetramer dissociation upon mutation in micelles (gray) and vesicles (black) is 
shown. L26F, S31N, I33A, and L38F mutations stabilize tetramer formation in both 
environments, whereas H37A is destabilizing (7) B, The normalized AraTM results for 
AM2 mutations.  Error bars represent standard deviations.  
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Figure 6 2. Excitation scans of cytoplasmic pHluorin2 expressed in HEK293 cells 
clamped at the indicated pH using K+ ions and nigericin are shown. Data are 
representative of three independent experiments (6). 
 
 
 
6.2 Identification of Critical Residues that Governs Receptor for Advanced 
Glycation Endproducts (RAGE) Homodimerization 
RAGE is a multiple ligand receptor that is associated with various chronic 
pathologies, including cancer, neurodegeneration, atherosclerosis, and diabetic 
complications (8). Homodimerization of RAGE is essential for proper RAGE signaling 
and leads to various inflammation-related cell responses (9, 10). In order to treat 
diseases associated with RAGE, one option is to block RAGE mediated signaling via 
homodimerization disruption. In order to accomplish this goal, first we need to identify 
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important residues that drive homodimerization of RAGE. Therefore, one future 
direction we can pursue is to identify the residues that govern RAGE homodimerization 
which can be later used for the drug design target. 
From our AraTM results on different RAGE truncations, we discovered that 
homodimerization of RAGE was mediated by the juxtamembrane region within the 
cytosolic tail (A375-P394). If we take a look at the sequence within this region (Fig. 
2.7), there are a lot of charged amino acid residues including many glutamic acid 
residues. In Chapter 2, we mentioned that it is possible that this glutamic acid rich 
region could adopt coiled-coil like structures that mediates protein-protein interaction. 
Therefore, we thought this is a good starting point. We made several point mutations on 
these charged residues within RAGE cytosolic tail and tested with AraTM Assay. As 
shown in Figure 6.3, our preliminary results showed that none of these mutations were 
sufficient to disrupt RAGE homodimerization. It is possible that we haven’t found the 
“hot spot” for RAGE homodimerization. Therefore, a comprehensive mutation 
screening could be done to identify the “hot spot”.  
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Figure 6. 3.  AraTM results on point mutations within RAGE cytosolic tail. Point 
mutations were made so that each charged residue was replaced by an alanine residue. 
No single mutations were sufficient enough to disrupt RAGE homodimerization. The 
results were normalized to wild-type PR-TM-CYTOfull RAGE AraC fusion protein and 
error bars represent standard deviations.  
 
 
 
6.3 Application of Modified DN-AraTM Assay as an Positive Selection Tool for 
Peptide-based Protein Homooligomer Blocker Design 
 In Chapter 3, we developed an assay, named DN-AraTM, which produces a 
chimera containing wild-type AraC co-expressed with a chimera that contains a non-
functional, mutant AraC (AraC*) that is unable to activate gene transcription. 
Preferential heterodimerization (AraC-AraC*) reduces the level of GFP reporter gene 
transcription (under control of the araBAD promoter) relative to homodimerization 
(AraC-AraC). The DN-AraTM enables simultaneous measurement of 
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homodimerization and heterodimerization of type I receptor domains, including both 
soluble and transmembrane (TM) domains, in their native orientation. Additionally, 
there is a very important potential application for this assay: a small peptide-based drug 
design system.  
Numerous disease states are associated with oligmer formation of proteins, such 
as Alzheimer’s disease. Oligomers of amyloid β-peptide (Aβ) are the earliest effectors 
that induce long-term potentiation (LTP) and lead to Alzheimer’s disease (11-13). Small 
molecules that inhibit Aβ oligomer formation had been demonstrated by recent study to 
be effective in abrogation of LTP thus this shines light on a new mechanism of 
therapeutic intervention (14). Despite the fact that small molecule drugs often have the 
advantage of better oral bioavailability over peptide-based drugs, the peptide-based 
drugs are superior in terms of high potencies of action and few off-target side-effects 
(15). Therefore, designing peptide-based drugs that block oligomer formation is a 
rational approach for next generation drugs.  
An ideal tool to assist the peptide-base drug design process needs to allow for 
the identification of the best target protein binding sequence among thousands of 
randomized peptide sequences in high efficiency. Therefore, one future direction for 
DN-AraTM assay is to use it as the foundation for the modified DN-AraTM assay, by 
replacing the reporter GFP with a lethal toxin gene for E. coli, we could build a positive 
selection system. The modified DN-AraTM assay would be designed as follows: first, 
the protein target is expressed as the AraC fusion protein and a library of randomized 
blocker peptide sequences will be expressed as AraC* fusion proteins. When 
homodimerization is preferred, the transcription of lethal toxin gene would kill the E. 
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coli cells with this genotype. Only when heterodimerization is preferred would one 
observe the survival of cells. By DNA sequencing the surviving cells, candidates that 
block target protein homooligomerization can be identified. Moreover, potential choices 
of lethal genes such as RelE (Endoribonuclease RelE) and ChpAK (Endoribonuclease 
MazF) of E. coli toxins have been shown to be effective in cell killing (16). As shown 
in Fig. 6.4, we replaced the GFP by RelE gene in the DN-AraTM, expressed both types 
of integrin αIIb AraC chimeras (wild-type and obligated homodimer mutation L980A), 
and monitored cell growth by optical density at 600nm (OD600). The results showed 
that, first, RelE gene expression leads to repression of cell grown could be governed by 
homodimerization of AraC chimeras. Second, we observed a more remarkable 
repression of cell growth for the L980A integrin αIIb AraC chimera relative to wild-type 
integrin αIIb AraC chimera, which fits well with the expectation that stronger 
homodimer of chimera construct results in higher expression of RelE gene, thus, more 
cell death. Both observations support the potential usage for modified DN-AraTM as a 
positive selection system for drug screening. 
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Figure 6. 4.  Modified AraTM assay utilizing toxin RelE as the reporter for positive 
selection. Obligated homodimer-forming integrin αIIb L980A mutant AraC chimera 
(L980A) had a stronger activation on araBAD promoter for RelE expression that leads 
to more cell growth repression compared to wild-type integrin αIIb AraC chimera (wt) as 
well as cells not expressing any AraC chimera (Negative). Error bars represent standard 
errors (Negative: negative control, L980A: integrin αIIb L980A mutant AraC chimera, 
and wt: wild-type integrin αIIb AraC chimera). 
 
 
 
6.4 Application of Modified DN-AraTM Assay that Reports Homodimer and 
Heterodimer Simultaneously for Drug Design Optimization 
An ideal peptide-based drug should have two characteristics: first, it should have 
a high specificity against the receptor target. Second, it should not form aggregates that 
interfere with its therapeutic efficiency. Therefore, when designing a drug, it would be 
beneficial to have a system that could report heterodimer (specificity of the drug to its 
target) and homodimer (tendency to form aggregates) in an equilibrium system 
simultaneously. This leads us to another future direction for the DN-AraTM assay: 
modify the araBAD promoter so it requires two types of transcription factors for 
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transcription activation. As shown in Figure 6.5, binding of wild-type AraC to high-
affinity O2 and I1 sites forms a DNA loop and represses gene transcription of araBAD 
promoter (17). In the presence of arabinose, the wild-type AraC protein homodimerize 
in another orientation and bind to I1 and I2 sites. This opens up the DNA loop thus RNA 
polymerase can bind and gene transcription is allowed. In our DN-AraTM assay 
(Chapter 3), we replaced the N-terminal domain of wild-type AraC protein (including 
arabinose binding pocket and N-terminal dimerization domain) with the protein domain 
of interest. Thus, the DNA loop formation is now arabinose independent but protein 
homo/heterdimerizaiton dependent.  
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Figure 6. 5.  Binding of AraC in trans to the O2 and I1 half-sites to form a DNA loop in 
the absence of arabinose and its binding cis to the I1 and I2 half-sites in the presence of 
arabinose that leads to unlooping and induction of pBAD and transient depression of pc 
and the light-switch mechanism (17).  
 
 
 In the modified DN-AraTM assay, we would like to replace the high-affinity I1 
site with another transcription factor binding site on the pAraGFPCDF plasmid 
(Chapter 3) and the AraC part of the chimera protein expressed by pAraTMDN 
(Chapter 3) with another transcription factor protein. We would also replace the reporter 
GFP gene on the modified pAraGFPCDF with RFP (red fluorescent protein) gene. 
Then, the modified reporter plasmid would have reporter gene controlled by two 
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transcription factor binding sites. In the experimental setup, we would co-express all 
four plasmids: pAraTMwt (Chapter 3), modified pAraTMDN, modified pAraGFPCDF, 
and pAraGFPCDF. As a result, heterodimerization of the two types of chimera proteins 
expressed by pAraTMwt and modified pAraTMDN could be monitored by RFP signal 
and homodimerization of chimera proteins expressed by pAraTMwt could be correlated 
to GFP signal. 
Ideal replacement candidates would have a functional truncated protein 
(including its DNA-binding domain (DBD)) that is similar to truncated AraC (used in 
DN-AraTM assay) in size with well-studied DNA-binding site consensus sequence. 
One possible candidate is the Streptomyces griseus AdpA, which had been described by 
previous studies with a functional truncation that is 126aa in size (compared to 
truncated AraC that is 125aa) and known binding site consensus sequence 5’-
TGGCGGGTTC-3’ (18). As an initial attempt, we replaced the I1 site sequence with the 
10bp AdpA consensus sequence on the DN-AraTM assay reporter plasmid 
(pAraGFPCDF) and the AraC* protein gene on the pAraTMDN plasmid with DNA 
sequence that translates to truncated AdpA protein (residue 215-340). Then we 
expressed or co-expressed pAraTMwt, modified pAraTMDN, and modified 
pAraGFPCDF with each of pAraTMwt and modified pAraTMDN expressing integrin 
αIIb L980A as the protein domain of interest. The results are shown in Figure 6.6. All 
three scenarios showed similar fluorescent signals (expressing modified pAraGFPCDF 
alone, co-expressed pAraTMwt with modified pAraGFPCDF, or co-expressed 
pAraTMwt, modified pAraTMDN, and modified pAraGFPCDF). Two conclusions 
could be made from these results. First, by replacing the native I1 with the AdpA DNA-
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binding sequence, homodimerization of AraC fusion proteins cannot activate the 
AraC/AdpA dual promoter. Second, heterodimerization of AraC and AdpA fusion 
proteins can not activate the AraC/AdpA dual promoter. The inability to turn on 
modified AraC/AdpA dual promoter may be due to incorrect spacing between the two 
transcription factor binding sites. Therefore, further optimization of the spacing between 
these binding sites is required.  
 
 
Figure 6. 6. Modified AraTM assay utilizing two transcription factor binding site as the 
mechanism to control GFP expression. Neither homodimeriztion of AraC fusion 
proteins nor heterodimerization of AraC/AdpA fusion proteins could activate the 
AraC/AdpA dual promoter on the modified pAraGFPCDF plasmid (Negative: negative 
control only expressing modified pAraGFPCDF plasmid, AraC: co-expresseing 
pAraTMwt with modified pAraGFPCDF plasmids, and AraC + AdpA: co-expressing 
pAraTMwt, modified pAraTMDN, and modified pAraGFPCDF plasmids). 
 
 
 
 
 
 153 
6.5 Determination of High-resolution Human RAMP1 Structure by X-ray 
Crystallography 
 In Chapter 4, we designed an E. coli-based membrane protein overexpression 
system, pOmpF expression plasmid, which utilizes an engineered bacterial outer 
membrane protein F (OmpF) as the fusion to enhance target protein expression. Using 
this technique, we were able to make milligram quantities of pure full-length human 
RAMP1 protein. One future direction is to apply this method to purify enough human 
RAMP1 protein to set up crystallization tests for high-resolution structural studies. Even 
though structure of RAMP1 extracellular domain had already been solved, there is still 
no information on how the RAMP1 extracellular ligand-binding pocket is orientated 
respect to its TM domain (19). Considering the important role RAMP1 TM domain 
plays in signaling, including its role in forming heterooligomer with CLR, there is still 
great value in solving the full-length human RAMP1 structure (20). This structural 
information could not only provide insights in how RAMP1 is inserted into the cell 
membrane but also help in predicting which side of the RAMP1 TM domain is facing 
the CLR TM domains.  
 
 
6.6 Identification of CLR-RAMP1 Association Interfaces through Cysteine 
Mutagenesis and Cross-linking 
In Chapter 5, we identified a specific RAMP1 TM motif that governs the 
heterodimerization of CLR and RAMP1 and affects their signaling as a CGRP receptor. 
This finding is especially critical for anti-migraine drug design since it is often very 
difficult to develop small molecule antagonists against family B GPCR to compete with 
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their endogenous peptide-based ligand (21). One solution is to design allosteric 
regulator that does not inhibit receptor signaling by direct antagonist/agonist 
competition, instead, it inhibits receptor signaling by binding to locations on the 
receptor that modifies its ligand binding site and prevents ligand binding. However, in 
order to achieve this goal, we need to complete the other half of the picture, which is, 
how CLR TM domains interact with RAMP1. Therefore, one future direction that is 
worth exploring is to figure out what CLR TM domains are associating with RAMP1 
and more specifically, which at which interfaces do these protein interact.  
The experimental techniques that could be used are site-directed mutagenesis 
and cysteine cross-linking. This should be done by first performing a series of 
mutagenesis reaction to generate single cysteine residue substitution on each full-length 
CLR and RAMP1 protein TM domains. Then, the proteins would be expressed in HEK 
cells and cross-linked the free sulfhydryl group on the cysteine side-chain between 
mutant CLR and RAMP1 proteins using a maleimide crosslinker (Bismaleimidohexane) 
and immunoblotted with specific antibodies. Judging by the molecule size of the 
immunoblotted bands, we could determine which RAMP1 and CLR mutants were 
cross-linked thus their relative positions with respect to one another. In Figure 6.7, we 
successfully cross-linked HA-tagged RAMP1 I118C mutation with one of the CLR 
TM5 mutation (L290C) in HEK cells. This illustrates the plausibility of the 
experiments. Furthermore, by making single residue cysteine substitution on the 
RAMP1 TM and identified CLR TM domains at different faces of the helices and 
performing cross-linking experiments, CLR-RAMP1 association interfaces could be 
mapped out. 
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Figure 6. 7. CLR and RAMP1 cysteine cross-linking experiment. CLR and RAMP1 
can only be cross-linked when cysteine point mutations when introduced to each 
receptor. The lower molecule weight band corresponds to HA-tagged RAMP1 (20.9 
kDa) and the higher molecule weight band corresponds to HA-tagged RAMP1 cross-
linked to CLR (70.9 kDa) ((+): RAMP1-HA I118C and CLR L290C and (-): RAMP1-
HA wt and CLR wt). 
 
 
 
6.7 Final Remarks  
 
 In summary, this work contributes to the field of membrane protein research. 
More specifically, the tools we developed can benefit the exploration of membrane 
proteins such as identifying residues that define protein oligomerization as well as high-
resolution structural studies. Additionally, these tools can also be utilized as foundations 
for novel drug development methods. The findings regarding CLR and RAMP1 provide 
insights about their mode of association and signaling. However, this thesis only brings 
us a step closer in understanding many membrane protein-linked biological processes. 
 156 
Thus, many future research directions were suggested. It’s my hope that this work 
provides motivation for individuals who are enthusiastic and passionate to carry on.   
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